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ABSTRACT
Transcriptional activation domains require coactivators or adaptors in
order to stimulate transcription. The ADA genes - ADA 1, ADA2, ADA3, ADA5,
and GCN5 - were identified in a genetic screen designed to isolate mutations in
genes which encode transcriptional adaptors. ada strains have the phenotypes
expected of such adaptor mutants. They are defective in transcriptional
activation both in vivo and in vitro. The activation potentials of both the VP16
and the GCN4 activation domains are greatly reduced in the absence of ADA2,
ADA3, or GCN5. Furthermore, the fusion of ADA2 or ADA3 to a heterologous
DNA binding domain creates a transcriptional activator that is tightly regulated
by the levels of the other ADA genes. This suggests that in vivo the ADA
proteins form a complex which mediates the activation of transcription.
In vitro studies demonstrate that the ADA complex binds the VP16
activation domain. In yeast nuclear extracts, ADA2 and full length VP16
coimmunoprecipitate. However, this interaction is not detected with a truncated
version of VP16. Truncated VP16 has very little activity in vivo. Furthermore,
the VP16 activation domain was shown to directly interact with both ADA5 and
ADA2. The biological relevance of these interactions is demonstrated by the
finding that neither ADA2 nor ADA5 bind to a variant of VP16 which has a
double phenylalanine to alanine substitution. This mutant has very little
transcriptional activation potency in vivo.
ADA, SRB2 double deletion mutants have a synthetic phenotype, and
deletion of an ADA gene exacerbates the phenotypes caused by truncations of
the CTD. Together these data suggest that the ADAs function in parallel to the
SRBs and that they function with the CTD to mediate the activation of
transcription.
All the known ADA proteins cofractionate with RNA polymerase II when
purified from yeast extract. Furthermore, in vitro the ADA complex can bind the
CTD. This physical association between the ADAs and the CTD validates the
genetic interactions and suggests that some activation domains function, at
least in part, by recruiting the ADA-Pol II complex to promoters.
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Adaptors and Their Role in Transcriptional Activation
Part I: Introduction
Transcriptional activation
Transcriptional activation plays an important role in a wide range of
biological regulatory programs. Research from numerous labs studying many
different biological phenomena has elucidated a variety of signal transduction
pathways whose ultimate consequence is the transcriptional activation of target
genes. For example, steroid hormone-receptor complexes directly mediate
transcriptional activation of target genes (Yamamoto et al., 1992). More
complicated multi-step regulatory circuits are often used by environmental and
developmental signals to activate transcription of appropriate genes (McKnight
and Yamamoto, 1992). Recently transcriptional activation has also been shown
to be critical for learning and memory (Bourtchuladze et al., 1994; Huang et al.,
1994; Yin et al., 1994). This emphasizes the notion that transcriptional control, a
simple idea first discovered in studies of the E. coli lac operon (Beckwith and
Zipser, 1970), facilitates essential and complex physiological processes.
Two types of DNA elements are necessary for transcriptional activation.
One is the promoter element, which encompasses the sequences surrounding
the transcription start site. Promoters usually include a TATA-box found
upstream from the transcription start site. Those promoters that lack a TATA-box
have a conserved element termed the Initiator (Inr) at the transcription start site.
These promoter elements, the TATA-box or Inr, serve as the assembly site for
the transcription machinery (Zawel and Reinberg, 1993). The other type of
element, the UAS or enhancer, is often found at great distances from the
promoter element. In yeast, UASs are found hundreds of base pairs upstream
from the promoter, while in higher eukaryotes enhancers can be found
thousands of base pairs upstream or downstream from the promoter. UAS and
enhancer elements fulfill a similar role; they contain binding sites for
transcriptional activators (Guarente, 1988), which then stimulate transcription at
the distant promoter.
The TATA-box is sufficient to obtain accurate transcription initiation in
vitro. This minimal reaction, which has been termed basal transcription,
requires the general transcription factors (GTFs) as well as RNA polymerase II
(Pol II). The GTFs include the TATA-binding-protein (TBP) which binds to the
TATA element nucleating the assembly of the transcription initiation complex.
The other general transcription factors, which include TFIIA, TFIIB, Pol II, TFIIF,
TFIIE, and TFIIH, bind to the TBP-DNA complex (Conway and Conway, 1993).
In vitro these factors are able to bind the TBP-DNA complex stepwise to form a
preinitiation complex which can initiate transcription after addition of
nucleotides (Buratowski et al., 1989). However, it is not clear whether the
stepwise assembly of the preinitiation complex or the basal transcription
reaction occur in vivo.
One of the central problems in molecular biology is how transcriptional
activation is mediated over long distances. Activators are often positioned far
upstream at UASs and must communicate with their targets, the general
transcription factors, at the promoter. This is believed to occur by looping-out
the intervening DNA allowing for contact between the activators and the general
transcription machinery (Dunaway and Droge, 1989; MOiller-Storm et al., 1989).
Activated transcription can also be recapitulated in vitro; it requires a template
with UAS and TATA elements as well as transcriptional activators, the GTFs,
and other intermediary factors (see below for more details) (Tjian and Maniatis,
1994). However, activated transcription in vitro cannot reproduce the same
high level of activation detected in vivo nor can activators function over the
same distances that occur in vivo (Lue and Kornberg, 1987; Miller-Storm et al.,
1989).
In order to function, transcriptional activators require two domains (Hope
and Struhl, 1986). One, the DNA-binding domain, endows activators with
specificity to affect only the appropriate target genes by binding to specific UAS
elements. The other important domain, the transcriptional activation domain, is
responsible for stimulating the initiation of transcription. Activation domains are
often characterized by their amino acid composition. Many activation domains
are rich in acidic amino acids and these domains are found in all eukaryotes
(Triezenberg, 1995). Yeast acidic activation domains function in mammalian
cells and vice versa implying a conserved mechanism of action for acidic
activation domains (Guarente, 1992). Other types of activation domains have
been characterized in mammalian systems including glutamine rich, proline
rich, isoleucine rich, or serine/threonine rich. However, these types of activators
do not function in yeast (Kinzler, 1994; Ponticelli et al., 1995).
Activation domains interact with general transcription factors in
vitro
The mechanism by which activation domains stimulate transcription has
been the focus of much research during the past few years and several models
have been proposed. One model of activation argues for direct contact
between activation domains and the general transcription factors. The
activation domain from the virion protein 16 of Herpes simplex virus (VP16),
perhaps the best characterized acidic activation domain (Cress and
Triezenberg, 1991; Regier et al., 1993), has been shown to directly interact with
several general transcription factors. This concept of a direct interaction
between activation domains and the GTFs is appealing because one obvious
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mechanism to activate transcription would be to recruit general transcription
factors to promoters. Direct interactions have been detected between VP16 and
TBP, TFIIB, as well as the p62 subunit of TFIIH (Ingles et al., 1991; Lin and
Green, 1991; Lin et al., 1991; Stringer et al., 1990; Xiao et al., 1994). All of
these interactions have been shown to depend on a functional VP16 activation
domain, arguing for the biological relevance of these interactions. In addition,
mutant TBP and TFIIB molecules which no longer bind activation domains also
do not support activated transcription in vitro (Kim et al., 1994a; Roberts, 1993)
However, the requirement for these in vitro interactions for activated
transcription is not clear. The mutant TBP referred to above, which does not
support activated transcription and does not bind VP16 in vitro, also does not
interact with a TATA-box nor does it support recruitment of TFIIB. The effects of
this mutation on other known TBP interactions, such as with TFIIA or the TBP
associated factors (the TAFs, see below) were not tested (Kim et al., 1994a).
Thus, it is unclear what contribution the defect in binding VP16 makes to its
inability to support activated transcription.
A number of studies have isolated TBP mutants based on their inability to
support activated transcription in vivo. These mutants were then tested in vitro
to determine what biochemical defects they possessed. In one study (Tansey et
al., 1994), a strong correlation was observed between the inability to support
activated transcription in vivo and the inability to bind TAFII250 (see below for
discussion of the TAFs) in vitro. Another study isolated a TBP mutant unable to
support activated transcription in vivo and unable to bind TFIIA in vitro.
Furthermore, fusion of the smaller subunit of TFIIA to this mutant TBP partially
rescues the activation defect, arguing that in vivo the stimulation of the TBP-
TFIIA complex is (one of) the mechanism(s) of activation (Stargell and Struhl,
1995). Still other TBP mutants, that do not support activated transcription in
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vivo, show reduced affinity for DNA in vitro (Arndt et al., 1995). The study of TBP
mutants that are activation defective in vivo has not yet uncovered a link
between transcriptional activation and the binding of activation domains to TBP.
Therefore, while the function of TBP during transcriptional activation appears to
be very complex involving interactions with many factors, it is unclear whether
direct interactions between activators and TBP play a crucial role. Furthermore,
Tansey et. al. have shown that some TBP variants defective in DNA binding and
in vitro transcription function well in vivo indicating that the in vitro model system
does not completely mimic the in vivo situation.
Interactions between TFIIB and the VP16 activation domains have also
revealed several interesting findings. Acidic activation domains can bind TFIIB
directly and recruit TFIIB to the TBP-DNA complex (Lin and Green, 1991; Lin et
al., 1991). Moreover, this interaction causes a conformational change in TFIIB
(Roberts and Green, 1994). Choy and Green have shown that the interaction
and recruitment of TFIIB are not sufficient for activated transcription in vitro. In
these experiments, activated transcription requires the presence of the TBP-
associated-factors (TAFs, see below) suggesting that activation may involve at
least two steps, a TAF independent TFIIB recruitment step and then a TAF
dependent step (Choy and Green, 1993). The importance of VP16 mediated
TFIIB recruitment for in vitro transcription was demonstrated by the isolation of a
TFIIB mutant which does not bind VP16 and does not support activated
transcription in vitro (Roberts, 1993). However, it is not clear that these are the
only defects caused by this mutation, especially considering that it is a double
amino acid substitution. The effects of this mutation on TFIIB function have not
yet been tested in vivo, and, given the differences observed with TBP mutants in
vivo versus in vitro, this is a significant caveat.
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The discovery of adaptors
Other models for activation posit that intermediary factors, referred to as
coactivators, mediators, or adaptors, are necessary to mediate the effects of
activation domains (Berger et al., 1990; Kelleher III et al., 1990; Pugh and Tjian,
1990). These intermediary factors are proposed to be necessary for at least two
different functions. One type of factor is proposed to bridge the interaction
between general transcription factors and activation domains. However,
transcriptional activation requires more than a simple bridge between activators
and the GTFs, because in vivo DNA is packaged into chromatin which is known
to inhibit transcription. Therefore another class of factors which counteracts
chromatin mediated repression is thought to be necessary for activation in vivo
(Guarente, 1995). Using a variety of approaches many labs have identified a
number of adaptor-type proteins. The remainder of this chapter will consider
the role of these adaptor-type molecules in transcriptional activation as well as
the multiple interactions that have been documented between activation
domains and these potential targets.
Experiments involving in vitro transcription reactions first suggested that
proteins beyond the defined general transcription factors are necessary for
activated transcription. Tjian and colleagues found that recombinant TBP could
support basal transcription but not activated transcription in vitro, whereas the
purified transcription factor lID (TFilD), which contains TBP, could support
activation. This result implied that TBP associated factors (TAFs) present in the
TFIID fraction are necessary for the activation process (Pugh and Tjian, 1990).
In a different approach it was found that in vitro transcription could be inhibited,
or squelched, by addition of excess exogenous transcriptional activator. This
inhibition could be counteracted with the addition of a partially purified factor,
termed the mediator, that is proposed to link activation domains with the general
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transcription factors (Flanagan et al., 1991; Kelleher III et al., 1990). Likewise,
the in vitro inhibition resulting from excess activator could be modulated by
preventing the exogenous activator from binding DNA. In this case, the
exogenous activator inhibited activated transcription but not basal transcription
suggesting the activator bound to and sequestered a factor, termed an adaptor,
necessary for activated but not basal transcription (Berger et al., 1990).
Part II1: Isolation and Characterization of Mammalian Coactivators
The TAFs
Subsequent to finding that TBP was not functionally equivalent to TFIID
for activated transcription, TFIID was shown to consist of TBP plus
approximately eight tightly associated factors referred to as TAFs (Dynlacht et
al., 1991). Reconstitution of the TAFs with TBP is sufficient in vitro for activated
transcription with a number of different types of transcriptional activators. Many
TAFs have been cloned, and some have been shown to bind specific activation
domains. For example, dTAFI11 0 interacts with the glutamine rich activation
domain of Spl (Gill et al., 1994; Hoey et al., 1993), and dTAF1140 interacts with
the VP16 activation domain and with TFIIB (Goodrich et al., 1993).
The importance of these interactions has been probed by a number of
methods. Anti-TAF1140 antibodies inhibited activated transcription in vitro
suggesting that the interaction of TAFII40 with activators and basal factors is
important for activated transcription (Goodrich et al., 1993). A more compelling
result is that activation competent partial TBP-TAF complexes can be
assembled with recombinant components. Complexes containing TBP,
TAFII250 (the core component of the TFIID complex on which the other factors
assemble), as well as the particular TAF protein which interacts with the
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activation domain being tested (for example TAFII110 with Spl) are sufficient
for activated transcription in vitro (Chen et al., 1994b).
Additionally, recent experiments with reconstituted TBP-TAF complexes
have demonstrated synergistic activation in the presence of two transcriptional
activators when the TAF target for each activation domain was present (Sauer
et al., 1995a; Sauer et al., 1995b). Synergism occurs when the activation
produced by two (or more) activators at one promoter is greater than the sum of
activity that occurs with individual activators. In these experiments, synergism
was observed at the molecular level by the increased binding of TFIID to the
promoter. The TFIID complex has also been shown to be the in vitro target of
the synergism mediated by multiple VP16 or ZEBRA (an activator from Epstein-
Barr virus) activation domains. In this case, synergism was also demonstrated
by increased TFIID TATA-box binding (Chi et al., 1995).
Much of the work to date on the role of the TAFs in transcription has
utilized in vitro transcription reactions, however identification of TAF containing
complexes in yeast has enabled their in vivo function to be examined. The
yeast TAFs (yTAFs) were originally identified by Weil and colleagues (Poon et
al., 1994; Poon and Weil, 1993). Other workers have also identified a TFIID-like
TAF complex in yeast extracts and have demonstrated that the complex can
support transcriptional activation in vitro (Reese et al., 1994). All cloned yTAFs
are homologous to TAFs from mammals and insects and are essential for
viability (Struhl, 1995). Recent experiments using conditional alleles of the
various yTAF genes indicate that the yTAFs may not have a specific effect on
activated transcription, but rather may be required for transcription in general.
In the absence of yTAFII130 (which is homologous to human TAFII250 the
central component of the TFIID complex), the relative level of activated
transcription at the HIS3 and CUP1 genes remained high. On the other hand,
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constitutive transcription of HIS3 decreased steadily (Struhl, 1996b). These
findings cast doubt on the role of the TAFs in activated transcription in vivo.
Instead, like the general transcription factors, the yTAFs appear to be necessary
for all transcription. The lethality of null mutations in yTAF genes is also
consistent with a general role in transcription. They do not have the subtle
effects on viability and transcription expected of a coactivator.
A role for TAFs in processes other than transcriptional activation has
been suggested. TAFs may play a role in repressing basal transcription since,
in the absence of activators, TFIID initiates transcription less efficiently than TBP
(Chi et al., 1995). In addition, TAF11150 has been demonstrated to be necessary
for promoter selection. The Drosophila ADH gene contains two promoters that
are utilized differentially during development (Corbin and Maniatis, 1989). It
was shown that the selective usage of the distal promoter during early
embryogenesis is mediated through its initiator element. Furthermore, the
regulation of promoter selection requires TFIID as well as TFIIA (Hansen and
Tjian, 1995). TAFII150 is essential for this selectivity which is consistent with
other findings demonstrating that it binds to promoter sequences found
downstream of the TATA-box (Verrijzer et al., 1994) These findings implicate
TAFII1O50 in the process of promoter selection, but not necessarily in mediating
transcriptional activation.
Other Mammalian Coactivators
Other coactivators have been identified both by biochemical fractionation
of mammalian in vitro transcription systems and by identification of novel
proteins which interact with activation domains. PC4/p15 was purified from
HeLa cell extracts as an activity necessary for optimal transcriptional activation
in vitro. The recombinant PC4/p15 protein was shown to bind directly to acidic
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activation domains as well as to the TBP-TFIIA-DNA complex. Although these
interactions create a direct link between activation domains and the general
transcription factors, PC4/pl5 mediated activation also requires the TAFs (Ge
and Roeder, 1994; Kretzschmar et al., 1994). This result is similar to the finding
that TFIIB can directly interact with and also be recruited to promoters by VP16.
However, transcriptional activation requires the TAFs. Interestingly, a yeast
homolog to PC4/pl5 was discovered in a screen for high copy suppressors of
conditional alleles of TFIIB. The yeast gene, SUBI, shows extensive identity to
PC4/pl5 in its N-terminal half. In addition the SUB1 protein has been shown to
bind to TFIIB, but not to TBP-TFIIA. In vivo, deletion of SUB1 is synthetically
lethal with conditional TFIIB mutations, suggesting that in vivo the yeast
PC4/pl5-like protein functions in conjunction with TFIIB during the activation of
transcription. An explanation for the differences between the biochemical
properties of PC4/pl5 and its yeast homolog may lie in their non-homologous
C-terminal region (Knaus et al., 1996).
Another set of mammalian coactivators, the p300/CBP class, was
identified by two different experimental approaches. The CREB binding protein
(CBP) was isolated because it binds the phosphorylated, transcriptionally
active, form of CREB (Chrivia, 1993). Furthermore, CBP has been shown to
interact with TFIIB in vitro, and expression of CBP potentiates CREB mediated
activation in tissue culture supporting the hypothesis that CBP is a coactivator
(Kwok et al., 1994). p300 is homologous, though not identical, to CBP and can
also bind to and potentiate transcriptional activation of CREB (Lundblad et al.,
1995). p300 was identified as a factor which is bound by the adenovirus E1A
protein during E1A mediated cellular transformation (Eckner et al., 1994). E1A
binding to p300 and CBP is believed to cause the E1A mediated inactivation of
the SV40 enhancer as well as the transcriptional repression of genes involved
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in the control of cellular proliferation. Interestingly, the p300/CBP class of
coactivators has several domains homologous to coactivators found in yeast.
For example, a bromo domain is found in mammalian coactivators such as
TAFII250 and CBP as well as in the yeast SWI2, GCN5, and SPT7 proteins.
Furthermore, CBP shares a cysteine rich domain with ADA2 that is a possible
zinc binding motif, suggesting a conservation of function between the CBP class
of coactivators and the ADA complex. (Please see below for more complete
information about these yeast coactivators.)
HMG proteins, non-histone components of chromatin, have also been
shown to function as coactivators. HMG2 was identified as a coactivator activity
required for optimal VP16 mediated activation (Shykind et al., 1995). HMG2
coactivation requires the TAFs as well as TBP, similar to PC4/pl5. However,
unlike PC4/p15, HMG2 does not appear to interact with either activation
domains or the general transcription factors. The conserved HMG-box found in
the HMG1 and HMG2 proteins is sufficient for this coactivator activity. HMG1/2
proteins are proposed to function by stabilizing a more active TFIID-TFIIA-DNA
complex (Shykind et al., 1995). Another HMG protein, HMG17 which is not
homologous to HMG1/2, has also been shown to function as a coactivator but
only in reactions using nucleosomal templates (Paranjape et al., 1995). Finally,
another class of HMG proteins, HMGI(Y)s, has been demonstrated to play an
essential role in the stereospecific assembly of a large cooperative enhancer
complex termed the enhanceosome (Tjian and Maniatis, 1994). This complex
contains three different transcriptional activators in addition to HMGI(Y) which
functions as an architectural factor necessary for forming the proper higher
order structure (Thanos and Maniatis, 1995). This model has similarity to the
proposal that HMG2 functions by stabilizing the optimal conformation of the
TFIID-TFIIA-DNA complex.
18
Part II: Yeast as a model system for transcription studies, in vivo
and in vitro
The Genetics and Biochemistry of Transcription in Yeast
The conservation of the structure and function of the transcriptional
machinery across all eukaryotic species, from yeast to mammals, makes
Saccharomyces cerevisiae exceptionally well suited for analyzing the in vivo
mechanism(s) of transcriptional initiation and activation (Guarente, 1992). The
conservation of mechanisms involved in yeast and metazoan transcriptional
activation was first noted by the similarities between UAS elements and
enhancers as well as the conservation of the TATA box (Guarente, 1988).
Furthermore, transcriptional activators often function by mechanisms that are
conserved throughout all eukaryotes. Mammalian activators, such as steroid
receptors, can function in yeast, and conversely yeast activators can function in
animal and plant cells.
Moreover, the identification and purification of the yeast TBP was crucial
for both mammalian and yeast transcription studies (Hahn et al., 1989). The
cloning of yeast TBP was essential for the study of mammalian in vitro
transcription systems because purification of human TBP had proven to be a
formidable task. By screening for sequence homologs of the yeast TBP gene,
the genes for TBP from humans, plants, and insects were isolated.
Furthermore, the high degree of conservation of TBP across all eukaryotes
solidified the notion that the mechanisms involved in transcriptional initiation
and activation would be similar in yeast and mammals (Fikes et al., 1990; Hoey
et al., 1990). Interestingly, the isolation of the yTBP gene demonstrated that it
was identical to a previously cloned gene, SPT15, which had been identified in
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a screen for mutants that affect promoter selection (Eisenmann et al., 1989).
This finding further highlights the notion that yeast genetics can be successfully
utilized to identify the factors necessary for transcription in vivo.
Subsequent to the isolation of TBP from extracts, the tools of yeast
genetics and biochemistry have identified many factors involved in transcription.
Not surprisingly, all of the general transcription factors identified in mammalian
systems have been identified in yeast. TFIIA, TFIIE, TFIIH, and TFIIF homologs
were purified by biochemical fractionation (Sayre et al., 1992). The yeast gene
encoding TFIIB, SUA7, was identified in a genetic screen for mutants that affect
transcriptional start site selection (Pinto et al., 1992). Moreover, the use of yeast
genetics has identified several groups of genes whose products are thought to
be involved in mediating transcriptional activation. Some of these screens,
such as the Ada or Srb selections, were designed specifically to identify
potential coactivator molecules (Berger et al., 1990; Nonet and Young, 1989),
while other screens, such as those for ccr, spt or swi mutants, selected for
mutants with broad transcription defects (Denis and Malvar, 1990; Herskowitz et
al., 1992; Winston, 1992). Subsequent analysis of these mutants has led to
interesting findings that are relevant to transcription in all eukaryotes.
The SPTs
The SPT genes were isolated in a selection for suppressors of the effects
of transposon insertions in the 5' region of yeast genes. The insertions, which
contain either a full transposon ( a Ty element) or only the long-terminal-repeat
of a Ty element (a a element), inhibit the transcription of these neighboring
genes (Winston, 1992). This effect is proposed to be due to promoter
interference; transcription from the a element promoter out-competes and
inhibits transcription from the promoter of the nearby yeast gene (Hirschman et
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al., 1988). The net effect of an spt mutation is often to lower transcription from
the a element promoter and to concomitantly increase transcription from the
neighboring gene (Winston, 1992). This implies that the SPT gene products are
involved in promoter selection.
Most of the spt mutants can be divided into two classes depending on
which transposon insertions they can suppress (Winston, 1992). As mentioned
above, SPT15 encodes TBP. Several other mutants, spt3, spt7, spt8, and
spt20, have a suppression profile similar to spt15 mutants. The proteins
encoded by this group of genes, referred to as the TBP class, are proposed to
function by modulating the affinity of TBP for different promoters or the activity of
TBP at different promoters. This model is substantiated by the finding that SPT3
associates with TBP in yeast whole cell extract (Eisenmann et al., 1992).
However, it may be premature to conclude that all these gene products function
together since there are phenotypic differences among them. For example, spt7
and spt20 mutants share several phenotypes, such as inositol auxotrophy and
resistance to GAL4-VP16 mediated toxicity, which spt3 and spt8 lack (Marcus et
al., 1996). (SPT20 is identical to ADA5, see section below about the ADA
genes (Roberts and Winston, 1996).) This suggests that SPT20 and SPT7
proteins may function as part of the ADA complex whereas SPT3 and SPT8
may be more closely associated with TBP.
The other group of SPT genes, the histone group, derives its
classification from the fact that SPT1 1 and SPT12 encode histones H2A and
H2B (Winston, 1992). In yeast, the histones, H2A, H2B, H3, and H4, are
encoded by four loci: two of which encode H2A and H2B and two of which
encode H3 and H4. Addition or reduction in the copy number of any of these
loci causes an Spt- phenotype. In addition, deletions of the histone loci have
been shown to disrupt the phasing of nucleosomes at promoters. This effect on
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chromatin structure by spt mutants is consistent with various findings in vivo and
in vitro suggesting that chromatin structure represses transcription (Grunstein,
1990; Workman et al., 1991). The spt mutants in the histone class presumably
affect promoter selection by destabilizing chromatin structure.
The other members of the histone class, SPT4, SPTS, and SPT6 are also
thought to modify chromatin structure. As suggested previously, this could be
through the processing of histones, the assembly of nucleosomes, or the
physical association with histones in structured chromatin (Winston, 1992).
Consistent with the latter, recent experiments have shown that the SPT6 protein
can mediate nucleosome assembly in vitro (Bortvin and Winston, 1996).
The SWI/SNF Complex
The impact of chromatin on transcriptional activation has been further
highlighted by two other genetic screens that identified an overlapping set of
genes which function to counteract chromatin mediated transcriptional
repression. In one screen, the snf mutants were isolated based on the fact that
they can no longer transcribe the SUC2 gene (Carlson, 1987). The SNF genes
fall into two classes: SNF1 and SNF4 specifically activate transcription of
SUC2; while SNF2, SNF5 and SNF6 have more pleiotropic effects and genetic
interactions between these genes suggest they function as a complex. In a
second screen, the swi mutants were selected for their inability to transcribe the
HO endonuclease gene which is necessary for mating type switching. The swi
mutants also fall into two groups: mutants in the first group, swi4, swi5, and
swi6, have phenotypes specific to HO transcription; whereas swil, swi2, and
swi3, have more pleiotropic phenotypes (Herskowitz et al., 1992).
Subsequently, it was discovered that the swil, 2, and 3 mutants have
phenotypes similar to snf2, 5 and 6 mutants including defects in transcription of
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HO, SUC2, and IN04. Moreover, cloning studies revealed that SW12 and SNF2
are the same gene (Laurent and Carlson, 1992; Peterson and Herskowitz,
1992).
Suppression analysis led to the first indications that this group of genes
might function to counteract chromatin mediated repression. Mutations in SIN1
and SIN2, which encode chromatin proteins, suppress the transcription defects
of swi mutants. SIN2 encodes histone H3 and SIN1 encodes a HMG1-like
protein (Kruger and Herskowitz, 1991). Furthermore, the swi/snf mutants can
also be suppressed by the deletion of one of the histone H2A-H2B loci (sptl 1)
or by mutations in the nucleosome assembly factor SPT6 (Clark-Adams and
Winston, 1987; Hirschhorn et al., 1992; Neigeborn et al., 1987). At the DNA
level, the effects of snf2 or snf5 mutations can be detected by a change in the
chromatin structure at the SUC2 promoter. The alteration in micrococcal
nuclease digestion pattern suggests a change from open to closed nucleosome
structure in the mutant strains. sptl 1 mutations suppress the change in
nucleosomal structure caused by snf5 mutations (Hirschhorn et al., 1992).
Taken together, this suppression analysis argues that the SWI/SNF proteins
function by counteracting chromatin mediated repression.
Recently, the SWI/SNF complex has been purified from yeast whole cell
extract. This complex contains the SWI1, 2, 3 and the SNF5 and 6 proteins as
well as five other unidentified proteins (Cairns et al., 1994; Peterson et al.,
1994). One of these unknown proteins, now termed SNF11, was recently
cloned by a two-hybrid screen using SWI2/SNF2 as bait (Treich et al., 1995).
The SWI/SNF complex contains a DNA-stimulated ATPase activity, consistent
with the DNA-stimulated ATPase-like domain found in SNF2/SWI2. As
predicted by the genetics, the purified SWI/SNF complex is capable of
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disrupting nucleosomal structure and allowing transcription factors to bind a
chromatin packaged DNA template (C6t' et al., 1994).
The cloning of a mammalian SW12 homolog (Khavari et al., 1993;
Muchardt and Yaniv, 1993) made it possible to purify and characterize a
mammalian SWI/SNF complex (Imbalzano et al., 1994; Kwon et al., 1994). The
mammalian complex has very similar activities and components as compared to
the yeast complex. The human complex has been shown to facilitate the
binding of TBP and transcriptional activators, such as GAL4, to nucleosomal
templates. The first clue that the SWI/SNF family of genes is conserved
throughout evolution came from the discovery that brahma, an activator of
Drosophila homeotic genes, is homologous to SW12 (Tamkun et al., 1992).
The mechanism(s) by which the SWI/SNF complex is recruited to
promoters is not fully understood. Co-immunoprecipitation experiments
indicate that the SWI/SNF complex binds to the DNA binding domain of the
glucocorticoid receptor (Yoshinaga et al., 1992). However, the SWI/SNF
complex has recently been discovered to be a member of a even bigger
complex, the RNA polymerase II holoenzyme (see next section below for
details) (Wilson et al., 1996). This complex has been shown to bind to the
activation domain of VP16 and is thought to function as a bridge between
activation domains and the general transcription machinery. Neither of these
two findings, however, explain the observation that the SWI/SNF complex, in
isolation, facilitates the binding of TBP to chromatin templates in vitro in the
absence of activators.
The CCR4 complex
The properties of the CCR4 gene suggest that it is a glucose regulated
transcriptional adaptor (Draper et al., 1994). CCR4 suppresses the effects of
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SPT6 and SPTIO mutations. In particular, spt6 and sptlO strains have a
elevated level of ADH2 transcription when grown in glucose (normally the
repressed condition). A CCR4 mutation reduces this elevated level of
transcription (Denis and Malvar, 1990; Malvar et al., 1992). Furthermore, CCR4
is necessary for induction of ADH2 expression on ethanol containing media
(Malvar et al., 1992). The ethanol induced transcription of ADH2 is mediated by
the transcriptional activator ADR1 (Thukral et al., 1991), and ADR1 activity is
dependent on CCR4 (Draper et al., 1994). Furthermore, fusion of CCR4 to a
DNA-binding domain creates an activator which responds to carbon source
regulation (Draper et al., 1994). It is not clear how CCR4 is recruited to the
ADH2 promoter, but it is a necessary coactivator for ADR1. The future
characterization of two CCR4 associated proteins should shed light on the
molecular mechanism of this interesting coactivator complex (Draper et al.,
1994).
The SRBs and the RNA Polymerase II Holoenzyme
The largest subunit of RNA polymerase II has a unique and conserved
repetitive structure at its carboxy-terminus. This carboxy-terminal-domain,
known as the CTD, consists of multiple repeats of the heptapeptide sequence,
Tyr-Ser-Pro-Thr-Ser-Pro-Ser (Allison et al., 1985; Allison et al., 1988; Corden et
al., 1985). The number of repeats reflects genome complexity. For example
yeast Pol II has twenty-six repeats compared to the mammalian polymerase
which has fifty-two repeats (Corden, 1990; Young, 1991). In yeast and
mammalian cells these repeats are essential for viability (Allison et al., 1988;
Bartolomei et al., 1988; Nonet et al., 1987; Zehring et al., 1988). However,
partial truncations of the CTD cause conditional phenotypes. For example,
yeast cells expressing an RBP1 allele encoding only 11 heptapeptide repeats
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are viable but exhibit cold and temperature sensitivity as well as inositol
auxotrophy (Scafe et al., 1990). The inositol auxotrophy is due to a defect in
transcriptional activation of the IN04 gene. Using an a-amanitin resistant RBP1
gene, it was recently shown that the CTD is necessary for transcriptional
activation in mammalian cells (Gerber et al., 1995).
A selection for suppressors of the cold sensitivity caused by partial
truncation of the CTD identified nine SRB genes (Hengartner et al., 1995; Liao
et al., 1995; Nonet and Young, 1989; Thompson et al., 1993). Subsequently,
the nine proteins encoded by the SRB genes were shown to co-fractionate in a
large complex with the 12 subunits of RNA polymerase II (core RNA polymerase
II). This holoenzyme also contains the general transcription factors TFIIF, TFIIH,
and sometimes TFIIB (Kim et al., 1994b; Koleske and Young, 1994), but not TBP
and TFIIE. Interestingly, the holoenzyme is capable of supporting basal and
activated transcription in vitro with the addition of TBP and TFIIE. Activated
transcription occurs in the absence of the yTAFs (Kim et al., 1994b; Koleske and
Young, 1994). Furthermore, an SRB containing complex can be separated from
core RNA polymerase by treatment with either monoclonal antibodies directed
against the CTD or by fractionation over a CTD column, indicating that the SRB
complex binds the CTD as predicted from the genetics (Hengartner et al., 1995;
Kim et al., 1994b; Wilson et al., 1996). Either the solo SRB complex (referred to
as the mediator) or the entire holoenzyme can bind to the VP16 activation
domain, but not to non-functional VP16 variants (Hengartner et al., 1995). The
mediator can also support activated transcription when added to an in vitro
transcription reaction with core RNA polymerase II (Kim et al., 1994b). As
mentioned above, this complex (either the mediator or the holoenzyme) also
contains the SWI/SNF complex in stoichiometric amounts (Wilson et al., 1996).
In addition, the GAL1 1, SIN4 and RGR1 proteins have been shown to be a
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subcomplex that is part of the holoenzyme. These three proteins are of interest
because they have all been shown to necessary for the activation of some
genes and the repression of other genes (Jiang et al., 1995; Li et al., 1995).
Although all the SRB proteins behave similarly during biochemical
fractionation of yeast extracts, their genetic interactions with the CTD indicate
that they may play distinct roles in the control of transcription. Dominant gain-of-
function mutations in SRB2, 4 , 5, and 6 suppress CTD truncations, suggesting
that these genes are involved in stimulating transcription (Thompson et al.,
1993). However, deletion mutations of these genes cause different phenotypes:
SRB4 and SRB6 are essential for viability whereas SRB2 and SRB5 deletions
cause conditional phenotypes which are similar to partial CTD truncations. In
fact, deletion of SRB2 or 5 exacerbates the phenotypes of partial CTD
truncations. Together, these results suggest that the SRB4 and 6 proteins play
an essential role in conjunction with the CTD in order to activate transcription
initiation. On the other hand, SRB2 and SRB5 play a stimulatory role which
when hyperactivated can compensate for CTD truncations but when lost
exacerbate them. SRB7, 8, 9, 10, and 11 were isolated as recessive
suppressors of CTD truncations and deletions of SRB8, 9, 10, and 11 are viable
and suppress CTD truncations (Hengartner et al., 1995; Liao et al., 1995).
These data suggest that the recessive group of SRB proteins are responsible
for down-regulating the activity of polymerase through their interaction with the
CTD. In other words, weakening of the holoenzyme activity through a CTD
truncation can be compensated by removing SRB8, 9, 10, or 11 which are
negative regulators of CTD activity. SRB10 and 11, which are a cyclin/CDK
pair, presumably mediate their repressive effects by phosphorylating CTD,
although this has not yet been shown (Liao et al., 1995).
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These genetic findings suggest how other members of the holoenzyme
such as GAL1 1, SIN4 and RGR1 could affect both activation and repression of
transcription. These proteins have been shown to form a subcomplex within the
holoenzyme. RGR1 encodes an essential protein whose function is required to
retain SIN4 and GAL11 in the holoenzyme. The RGR1/GAL11/SIN4
subcomplex may function in a promoter specific manner to stimulate either the
recessive class or the dominant class of SRB proteins, thus activating or
repressing transcription (Li et al., 1995).
Mutations in the GAL 11 gene have been isolated in a number of genetic
screens. Most interestingly, it was shown that an allele of GAL 11, GAL 11P,
could bypass the need for the GAL4 activation domain by creating a new
protein-protein connection between the GAL4 DNA-binding domain and the
holoenzyme. This finding suggests that activation can be mediated in part by
recruitment of the holoenzyme to promoters (Barberis et al., 1995; Himmelfarb
et al., 1990).
Not surprisingly, a mammalian equivalent of the holoenzyme has been
identified by two groups. Schibler and coworkers have isolated a mammalian
holoenzyme-like complex from rat liver extracts. This complex contains, at least,
TBP, TAFs, TFIIB, TFIIE, TFIIF, and TFIIH in addition to core RNA polymerase II.
This complex is capable of supporting basal transcription, although its response
to activators was not examined (Ossipow et al., 1995). Furthermore, a human
gene homologous to SRB7 was found in the expressed-sequence-tags (EST)
data base. By following this protein during fractionation of calf thymus extract, a
mammalian holoenzyme was also characterized. However, this holoenzyme
required coactivators such HMG-2 and PC4 to activate transcription in vitro
(Chao et al., 1996). These findings strongly suggest that in mammals, as in
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yeast, RNA polymerase II is associated in large complex containing both
general transcription factors and other accessory proteins.
The ADAs
The ADA mutants were isolated in a selection designed to identify the
target of the VP16 acidic activation domain (Berger et al., 1992; Marcus et al.,
1994). Overexpression of the chimeric transcriptional activator GAL4-VP16,
which fuses the GAL4 DNA binding domain to the strong activation domain of
the Herpes simplex virus VP16, is toxic to yeast cells. Moreover, this toxicity
correlates with the ability of the chimera to activate transcription. In other words,
point mutations in the DNA binding domain that abolish binding also abolish
toxicity and, more importantly, point mutations that weaken the activation
domain also lessen toxicity. This correlation between activation potential and
toxicity suggests that toxicity is due to the sequestration of the general
transcription factors by GAL4-VP16. It was hypothesized that mutations in
adaptors, factors that bridge the interaction between the activation domain and
the transcriptional machinery, should alleviate this toxicity by disrupting or
weakening the connection between activation domains and the general
transcription factors (Berger et al., 1992). Strains resistant to GAL4-VP16
mediated toxicity, termed ada mutants, were selected. To date, five ADA genes
have been characterized; ADA 1, 2, 3, 5 and ADA4, which is allelic to a
previously isolated gene, GCN5 (Berger et al., 1992; Georgakopoulos and
Thireos, 1992; Horiuchi and Guarente, 1996; Marcus et al., 1994; Piia et al.,
1993).
The ADAs can be grouped into two classes. The best characterized
group includes ADA2, ADA3 and GCN5. The phenotypes of deletion mutations
in any of these genes are very similar. They have a striking slow growth
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phenotype on minimal media, are temperature sensitive, and have a marked
decrease in GCN4 and VP16 mediated transcriptional activation. Double
mutant combinations of any two of these genes have a phenotype no worse
than any single mutant. Also, when fused to a heterologous DNA binding
domain, ADA2 or ADA3 can activate transcription in a manner that is dependent
on the other ADAs. Together, these data suggest that in vivo the ADAs form a
complex which stimulates transcription (Berger et al., 1992; Horiuchi et al.,
1995; Pifia et al., 1993; Silverman et al., 1994).
In vitro, these proteins have the properties expected of a transcriptional
adaptor complex. ADA2 binds simultaneously to both ADA3 and GCN5
creating a trimeric complex where ADA2 is the linchpin (Horiuchi et al., 1995).
Furthermore, the ADA complex from crude nuclear extracts can bind the VP16
activation domain. The interaction occurs with the full length VP16 activation
domain, but not with an inactive truncation mutant (Barlev et al., 1995;
Silverman et al., 1994). In fact, ADA2 has been shown to be sufficient for this
specific interaction with the functional VP16 activation domain and the region of
ADA2 necessary for the VP16 interaction has been mapped to the N-terminal
one-third of the protein (Barlev et al., 1995).
The other group of ADA genes includes ADA1 and ADA5. The
fundamental difference between these two genes and ADA2, 3 and GCN5 is
that deletion mutants exhibit broader and more severe phenotypes. In
particular, ada I and ada5 strains grow slowly on rich media and display defects
in transcription at all the promoters tested. Also, mutations in either ADA 1 or
ADA5 cause an Spt- phenotype (Horiuchi and Guarente, 1996; Marcus et al.,
1996). In fact, an allele of ada5, spt20-61, was isolated in a screen for more spt
mutants of the TBP class. Additionally, spt7 mutants have phenotypes similar to
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ada5 strains including Ada- and inositol auxotrophy, suggesting that it may
function with ADA1 and ADA5 (Roberts and Winston, 1996).
The two groups of ada mutants share some phenotypes. GCN4
mediated activation is always severely defective in any of these mutants.
Moreover, double mutants combining the two classes, Aada2Aada5 strains for
example, have phenotypes which are no worse than the worst single mutant.
This suggests that all of the ADA proteins may function together in a single
complex or activation pathway but must play somewhat different roles (Marcus
et al., 1996). For example, ADA1 and ADA5 may play a central role in the ADA
complex that all (or most) activators utilize while ADA2, ADA3 and GCN5 serve
to link only certain activation domains, like GCN4, to the complex. Other
members of the complex might bridge the interaction with different activation
domains. In fact, consistent with the idea that multiple ADA proteins contact
activation domains, ADA5 as well as ADA2 has been shown to interact with the
VP16 activation domain (Marcus et al., 1996).
The mechanisms by which the ADA complex mediates its effects on
transcription are not fully understood. Barlev and coworkers showed that ADA2
protein is necessary for the binding of TBP (from crude nuclear extract) to VP16
and that ADA2 also binds TBP (Barlev et al., 1995). However, it is not clear how
direct the TBP-ADA2 connection is. At the genetic level, ada5 mutants have
some similarity to certain mutations in SPT15, the gene encoding TBP. spt15-
21 and ada5 strains are both inositol auxotrophs, and this allele of spt15 is
partially resistant to GAL4-VP16 mediated toxicity. Consistent with the in vitro
experiments mentioned above, this suggests that ADA5 may function by
interacting with TBP and that the mutation in spt15-21 disrupts the TBP-ADA5
interaction (Marcus et al., 1996).
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On the other hand, Chapter 3 of this thesis describes recent findings
arguing that the ADAs mediate their effect on transcription by interacting with
the CTD of RNA polymerase II. Briefly, partially purified ADA complex binds to
the CTD in vitro. Furthermore, RNA polymerase II cofractionates in a large
complex with all five ADA proteins. In vivo, partial CTD truncations in
combination with ada mutations cause synthetic lethality. This suggests that the
ADA proteins, like SRB2 and SRB5, are necessary for the full functioning of the
CTD during transcriptional initiation. Furthermore, double ada srb2 mutants are
lethal, arguing that the ADAs and these SRB proteins function in redundant
activation pathways. In all, these in vivo and in vitro data suggest that the ADAs
function by binding to RNA polymerase II in order to stimulate transcription. The
interaction between the ADA complex and activation domains further suggests
that the ADAs may function by recruiting Pol II to promoters. The inherent
contradiction between this model and the TBP interaction described above
could be resolved if the ADA-polymerase complex mediates and/or stabilizes a
link between Pol II and the TBP complex bound at the TATA box.
Recently, a GCN5 homolog was purified from Tetrahymena as a histone
H3 specific acetyltransferase. This suggests that the ADAs function by
acetylating histones, which is believed to "loosen" chromatin structure,
counteracting chromatin mediated transcriptional repression (Brownell et al.,
1996). This finding in conjunction with the fact that the ADAs are found in a
complex with Pol II may explain why there is a strong correlation between
acetylated histones and actively transcribed genes.
By screening the expressed-sequence-tags (EST) data base Berger and
colleagues have recently identified human homologs of both ADA2 and GCN5.
These human genes show extensive homology to their yeast counterparts, 31%
identity for hADA2 and 43% identity for hGCN5. The human genes do not
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complement in ada2 or gcn5 mutations yeast, but they do share a number of
properties with the yeast genes, including direct protein-protein interactions
between hADA2 and hGCN5 (Candau et al., 1996). The isolation of these
human genes opens an exciting avenue of research - the identification and
characterization of the mammalian ADA complex. Moreover, it highlights the
conservation of the mechanism(s) of transcriptional activation and implies that
what is learned about the yeast ADAs will directly apply to transcriptional
activation in mammals.
Part IV: Conclusions and Future Directions
The purification and cloning of TBP was a catalyst for a tremendous leap
in the understanding of transcriptional activation. It emphasized the similarities
between the yeast and metazoan transcription apparatuses as well as allowed
for the discovery of a new type of transcription factor, the coactivator or adaptor.
Numerous factors have been identified which are thought to mediate the
effects of activation domains. Some research, such as the characterization of
the TAFs, has focused on the purification of factors necessary for activated
transcription in vitro (Tjian and Maniatis, 1994). This direction has lead to the
identification of a plethora of factors as well as the detection of many direct
protein-protein interactions. Sometimes all of these findings seem
contradictory. For example, does VP16 interact with TAF1140, PC4, TBP, TFIIH
or TFIIB? Certainly, explanations consistent with all of these results are
possible; transcriptional activation probably involves multiple steps, all of which
may be targets of activation domains. However, many of these in vitro studies
suffer from a lack in vivo support. This is not a trivial concern as shown by
Tansey et. al. (as well as other workers with a more genetic approach, such as
F. Winston and colleagues) who demonstrated that TBP mutants which do not
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support transcription in vitro were fully functional in vivo for basal and activated
transcription (Arndt et al., 1995; Tansey et al., 1994). The importance of in vivo
experiments was also recently demonstrated by studies with conditional yTAF
mutants which suggest that TAFs are not required for activated transcription in
vivo (Struhl, 1996b).
In vivo approaches have focused on exploiting the powerful advantages
available in yeast to isolate genes whose products are involved in
transcriptional activation. These screens have isolated the SRB, ADA,
SWI/SNF, and SPT genes (Guarente, 1995). The role of the proteins encoded
by these different genes is not yet fully clear. However, biochemical
characterization of the SRB proteins has uncovered the existence of a new type
of complex, the RNA polymerase II holoenzyme, which contains core
polymerase plus various accessory proteins such as the SRB, GAL1 1, and
SWI/SNF proteins (Koleske and Young, 1995). The holoenzyme can support
activated transcription in vitro in the absence of the TAFs.
These findings have led K. Struhl to propose the Triad Model for
Transcriptional Activation (Struhl, 1996a). This model proposes that activation
occurs through activator recruitment of both TFIID and the holoenzyme. The
three-way interactions between the components involved (activator, TFIID, and
holoenzyme) will mutually reinforce each other. Thus recruitment of TFIID and
holoenzyme by the activator, which binds first by virtue of its high affinity for its
cognate binding site, will lead to significant transcriptional activation.
Furthermore, through the action of the holoenzyme associated SWI/SNF
complex the entire complex of activator, TFIID, and Pol II will be stabilized on
chromatin packaged promoters. This is a very appealing model because of its
simplicity in synthesizing the different coactivator studies. However, it does not
account for the involvement of other factors such as the ADAs, SPT3 and 8, and
34
CCR4 during transcriptional activation. Also, it does not take into account
studies that have suggested that at some promoters in vivo activation domains
stimulate transcription even when TFIID is already bound to the promoter (Chen
et al., 1994a). Furthermore, recruitment is not necessarily the only step during
transcription initiation which is stimulated by activators. How an initiation
complex consisting of all these various factors and stabilized by multiple
reinforcing interactions is able to begin transcription, which must lead to the
destruction of this complex structure, remains a mystery (Zawel et al., 1995).
Future studies will address many of these questions. Especially important is
how all these various factors work together. Or, it is possible they do not all
function at the same promoters; there certainly may be promoter specificity in
terms of which coactivators are used. Much work is also needed to characterize
the different interactions which have been studied in vitro to determine if they
are of significance for activation in vivo.
The role of the ADAs in transcriptional activation needs further
investigation. The association of the ADA complex with RNA polymerase II
suggests that they may indeed bridge the interaction between activation
domains and the transcriptional machinery, however their role in transcription
needs to be tested in vitro. The ADA-Pol II complex may behave similarly to the
holoenzyme, or it may need other factors such as the general transcription
factors and TAFs to allow for activated transcription. Also, the acetyltransferase
activity of GCN5 suggests that the ADAs may function to counter chromatin
mediated repression. In vitro this activity may best be demonstrated on
nucleosomal templates. Further purification of the complex should allow for the
identification of all the components of the ADA complex. Moreover, suppression
analysis of ada mutants should uncover other members of the complex and
illuminate the role of the ADAs in vivo. Equally important, all these factors
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probably have homologs in mammals and studying these factors should be very
exciting and lead to further advances for both systems.
In summary, the study of coactivators and their role in transcriptional
activation is at a very exciting juncture. Much future work will focus on
synthesizing how and if different factors and complexes work together during
activation. Also, analysis of all the interactions which have been characterized
between activation domains and possible targets should focus on their in vivo
relevance, as well as the mechanistic consequences these contacts have on
the initiation complex. Finally, the entire picture will not be complete until the
models explain the mechanism by which all these factors and interactions lead
to the very high level of synergistic transcriptional activation that occurs in vivo.
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Chapter 2:
Yeast ADA2 binds to the VP16 activation domain and activates
transcription
This chapter was previously published in Proceedings of the National Academy
of Science, USA, Volume 91, pages 11665-11668 in November 1994. The
authors were Neal Silverman, Julie Agapite, and Leonard Guarente.
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Summary
Previously it was shown that yeast ADA2 is necessary for the full
activity of some activation domains, such as VP16 and GCN4, in
vivo and in vitro. These results suggest that ADA2 functions as a
transcriptional coactivator or adaptor which bridges the interaction
between certain acidic activation domains and the basal
transcription machinery (Berger et al., 1992). Here we present two
findings consistent with this model. First, ADA2 interacts with a
region of the VP16 acidic activation domain that requires ADA2 for
activity in vivo. Second, ADA2, when fused to a heterologous DNA-
binding domain, can stimulate the activity of the basal transcription
factors in vivo. This ability of ADA2 to activate transcription is
mediated by ADA3, a gene with properties similar to ADA2 (Pifa et
al., 1993). These findings suggest that ADA2 has at least some of
the properties expected of a transcriptional adaptor.
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INTRODUCTION
Several models have been proposed to explain eukaryotic transcriptional
activation, including chromatin disruption by activators (Croston and Kadonaga,
1993; Workman and Kingston, 1992), and interaction between activators and
basal factors positioned at the TATA box (Ptashne, 1988). Direct interactions
have been demonstrated between the basal factors TFIIB or TBP and acidic
activation domains (Lin and Green, 1991; Stringer et al., 1990). These
interactions are disrupted by mutations in VP16 which prevent activation of
transcription (Ingles et al., 1991; Lin et al., 1991). Further, mutations in TFIIB
which prevent activation also prevent binding of VP16 (Roberts et al., 1993).
However, it has been clearly demonstrated that these interactions are not
sufficient for the activation of transcription (Choy and Green, 1993; Dynlacht et
al., 1991), and many investigators have proposed that coactivators or adaptors
must exist to bridge the interaction between activators and the basal machinery
(Berger et al., 1990; Kelleher et al., 1990; Peterson et al., 1990; Pugh and Tjian,
1990).
Tjian and colleagues have shown that TATA-binding-protein (TBP) is
associated with a number of auxiliary factors (TAFs) which are necessary for
activated transcription in vitro (Dynlacht et al., 1991). In fact, it has been shown
that TAFil 1 10 interacts with the SP1 activation domain (Hoey et al., 1993), and
TAF 1140 interacts with the C-terminus of the VP16 activation domain. The
significance of this interaction was demonstrated by the fact that anti-TAFli40
antibodies blocked activation by GAL4-VP16 (Goodrich et al., 1993).
Likewise, ADA2 was proposed to encode a transcriptional adaptor or
coactivator because it is necessary for certain acidic activation domains to
function in vivo and in vitro (Berger et al., 1992). The ada2 mutant was
originally isolated based upon its ability to grow in the presence of high levels of
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the toxic chimeric activator GAL4-VP16. The toxicity caused by overexpression
of GAL4-VP16 correlates with its ability to activate transcription and to bind
DNA. This result suggested that toxicity is due to the sequestration of essential
general transcription factors by the activator at many sites throughout the
genome. The collection of mutants resistant to GAL4-VP16 also includes ADA3
(Pifia et al., 1993) and GCN5 (G. Marcus and L. G., unpublished), and mutations
in these genes affect cell growth and activation of transcription in a manner
similar to the ada2 mutation.
The hypothesis that ADA2, perhaps in concert with ADA3 and GCN5,
constitutes a transcriptional adaptor makes two key predictions. First, ADA2
should bind to those activation domains which require the integrity of ADA2 for
full activity. Second, ADA2 should interact with one or more of the basal
transcription factors. In this report we perform experiments that test directly
whether ADA2, or a complex containing ADA2, binds to the VP16 activation
domain. We also begin experiments to show that ADA2 interacts with the basal
transcription factors in vivo. The results are consistent with the hypothesis that
ADA2 is a transcriptional adaptor.
RESULTS AND DISCUSSION
To examine whether ADA2 binds VP16, we expressed ADA2 tagged with
the hemagglutinin epitope (HA) from the influenza virus (Kolodziej and Young,
1991), and determined whether this protein would co-precipitate with a chimera
containing the DNA-binding domain of GAL4 fused to residues 413-490 of
VP16 (Triezenberg et al., 1988). Yeast extracts containing tagged or untagged
ADA2 were prepared. The amount of ADA2 protein in both extracts was
comparable, as measured by Western analysis with ADA2 antiserum (data not
shown). The extracts and purified recombinant GAL4-VP16 were incubated
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together, and mixed with protein A-beads covalently coupled to monoclonal
antibody against the HA epitope (Harlow and Lane, 1988). After collecting and
washing the beads, proteins that bound to the anti-HA antibody were eluted
using a peptide consisting of the HA epitope and analyzed by Western blotting
(Field et al., 1988; Zhou et al., 1992).
Figure 1A shows a filter probed with the anti-HA antibody. Note a band
of 49kD, the predicted size of ADA2HA, that was specifically bound to the
beads. This protein was absent in the extract with untagged ADA2, verifying
that the indicated band is ADA2HA. The same samples were probed with
antibody to VP16 (Figure 1B), revealing that the GAL4-VP16 chimera was
bound to and eluted from the beads when mixed with extracts containing
tagged ADA2, but not untagged ADA2. This experiment shows that GAL4-VP16
binds to ADA2 or a yeast multi-protein complex containing ADA2.
In order to determine which portion of the GAL4-VP16 chimera interacts
with ADA2, we repeated the co-precipitation experiment with a purified
recombinant GAL4-VP16 derivative truncated at residue 456 of VP16. This very
preparation shows considerable activity in a transcriptional activation assay in
vitro (Berger et al., 1990). In experiments in which the full length GAL4-VP16
bound to tagged ADA2 (Figure 2A), the truncated protein did not bind to ADA2
at all (Figure 2B). Thus, residues in VP16 carboxyl to position 456 are essential
for binding to ADA2.
To compare the binding in vitro of ADA2 to full length but not truncated
GAL4-VP16, with the ability in vivo of VP16 to activate transcription and respond
to ADA2, a set of VP16 derivatives was fused to the DNA-binding and
dimerization domains of lexA (Pifa et al., 1993). Previous experiments have
indicated that VP16 could be separated into functional sub-domains (Goodrich
et al., 1993; Regier et al., 1993; Seipel et al., 1992). We utilized a set of
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derivatives with domains extending from residue 413 to residues 450, 456, 460,
or 470. Another derivative contained VP16 residues 452-490. We were unable
to use a construct containing lexA fused to residues 413-490 of VP16 because
this construct was toxic in ADA2+ (but not ada2-) cells (data not shown).
However, previous experiments showed that a GAL4 fusion to this region of
VP16 activated transcription in vivo and was reduced 5-10-fold in ada2 mutant
cells (Berger et al., 1992). The ability of the above lexA fusions to activate
transcription in vivo was monitored by a lacZ reporter containing a single lexA
operator site, both in ADA2+ and Aada2 strains.
The 413 to 470 domain of VP16 was active and highly dependent on
ADA2 (Figure 3). The activity of the 413-470 moiety was abolished by mutation
of the critical Phe442 residue to Ala (Cress and Triezenberg, 1991).
Importantly, the 413-456 moiety was inactive in vivo, even though the protein
was present at the same levels as the 413-470 fusion protein (data not shown).
Thus, the inability of the 413-456 moiety to bind to ADA2 in vitro correlates with
its inability to activate transcription in vivo. Other derivatives, truncated at
residues 460 or 450, were also inactive. These assays define an ADA2-
dependent VP16 activation domain encompassing Phe442 and extending to a
boundary between residues 460 and 470.
Interestingly, the carboxyl moiety of VP16 (containing residues 452-490),
shown previously to contact the Drosophila TAF40 as well as replication protein
A (Goodrich et al., 1993; Li and Botchan, 1993), was also active in vivo, but
showed a minimal requirement for ADA2 (less than two-fold). This is consistent
with earlier findings that some activation domains (e.g. GCN4) show a strong
dependence on ADA2, while others (e.g. GAL4 and HAP4) do not (Piia et al.,
1993). In all, these data suggest that VP16 contains at least two functional
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domains; one is the ADA2-dependent domain delineated above, whereas the
other is a very potent, ADA2-independent, activation domain at the C-terminus.
Given that ADA2 binds to VP16 and that this binding appears to be
important for activation in vivo, we considered two possible mechanisms. First,
if VP16 activity were down-regulated by the binding of a repressor or by internal
repression, ADA2 might potentiate activation by preventing repression.
Second, ADA2 might directly activate the basal factors, for example, by protein-
protein contact. By the latter model, ADA2 itself should possess the ability to
activate transcription. We, therefore, tested activation by a lexA-ADA2 chimera
(containing all of ADA2), which retained the ability to complement an ada2
deletion mutation. This chimera was expressed from the strong ADH1 promoter
on a 2g plasmid.
lexA-ADA2 was active, although only about 10% as active as the lexA-
VP16:413-470 construct (Figure 4). This activity decreased to background
levels when a similar reporter missing the lexA binding site was used (data not
shown). Further, the activity depended on the dose of lexA-ADA2 - i.e., activity
was reduced 3-fold when the chimera was expressed on a low-copy plasmid
(data not shown). A further indication of the significance of the activity of lexA-
ADA2 is its unique dependence on ADA3, a second gene identified by the
selection for GAL4-VP16 resistant mutants (Berger et al., 1992). This
dependence was demonstrated in two ways. First, the activity of lexA-ADA2
was reduced in a Aada3 strain, To show that this effect was specific, we tested
a fusion of lexA to the HAP4 activation domain. As shown in Figure 4 and
previously demonstrated, the activity of lexA-HAP4 was only slightly reduced in
the Aada3 strain (Piha et al., 1993).
However, the above requirement of lexA-ADA2 for ADA3 is not unique,
since certain activators, such as GCN4, also require ADA3 for full activity (Piia
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et al., 1993). Therefore, we carried out a second test of ADA3-dependence by
over-expressing ADA3 from a 2gi plasmid. In this case the activity of lexA-ADA2
was augmented about 5-fold above the levels observed in a wild type strain, but
the activity of lexA-HAP4 (Fig. 4) and lexA-GCN4 (data not shown) was not
affected at all.
Because the activity of lexA-ADA2 was sensitive both to a decrease and
increase in ADA3 levels, we infer that it reflects a true aspect of ADA2 function.
Further our findings suggest that ADA2 and ADA3 are part of a heteromeric
complex. We imagine that only a small percentage of the highly expressed
lexA-ADA2 is complexed with the other ADAs and that this fraction is
preferentially diverted away from the lexA site to bona fide yeast promoters.
Expression of high levels of ADA3 would increase the number of ADA
complexes available to bind to the lexA site. If the ADA complex is required for
stimulating transcription, then the observed stimulation of lexA-ADA2 activity by
over-expression of ADA3 would be expected.
In summary, our findings show that ADA2, or a complex containing
ADA2, binds to VP16, and that this binding is important for activation in vivo.
Further, they show that ADA2 itself can activate transcription, and that this
activity is highly regulated by the level of ADA3 in cells. These findings are
consistent with the hypothesis that ADA2, perhaps as a part of a complex,
functions as a transcriptional adaptor linking activators and basal factors at
promoters. Interestingly, the Cys-rich region at the amino-terminus of ADA2
shares significant similarity to a mammalian protein, CBP, which binds to the
active, phosphorylated form of CREB and may itself be a co-activator (Chrivia et
al., 1993). It will be important to determine the identity of all of the components
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in a probable ADA complex, and to ascertain how ADA2 stimulates the basal
factors.
MATERIALS AND METHODS
Plasmids. pADA2HA was constructed by using PCR to engineer an in-frame
Bg/ll site at the carboxy terminus of ADA2 as well as flanking HindIll sites. This
PCR product was then ligated into the Hindlll site of pDB20 (Becker et al.,
1991). From this plasmid a Smal-BgAl fragment containing the ADH1 promoter
and ADA2 was isolated and ligated into pHAH4 (Sugiono, 1993), which had
been digested with Sa/I, filled in with Klenow fragment, and then digested with
BgAl; this results in the fusion of one copy of the nine amino acid 12CA5 epitope
from the influenza hemagglutinin protein to the carboxy-terminus of ADA2
(Kolodziej and Young, 1991). Likewise the pADA2-6HisL was created by using
PCR to engineer six histidine codons fused to the carboxy-terminus of ADA2
and flanking Hindlll sites; this gene was then cloned as a Hindlll fragment into a
version of pDB20LBgill (Berger et al., 1992) with a unique Hindill site.
To create the LexA-VP16 fusion constructs, the Not site in pRS316
(Sikorski and Hieter, 1989) was destroyed by cutting with Notl, filling-in with
Klenow fragment, and religating, creating pRS316-Not. The PADH-lexA202-
TADH cassette was then purified from pADH-lexA202 (Piha et al., 1993) as a
Smal-Sa/l fragment and ligated into pRS316-Not creating pARS/cen-lexA202.
Fragments encoding the various VP16 regions with flanking Notl sites were
generated using PCR and cloned into the Notl site at the C-terminus of lexA202.
LexA-ADA2 contains lexA residues 1-202 fused to the entire coding
sequence of ADA2 (Marcus et al., 1994). pADH-lexA202-HAP4 was described
earlier (Piia et al., 1993) The 2p ADA3 overexpression plasmid was
constructed by using PCR to generate an ADA3 gene with flanking BamHI sites
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which was then cloned into the Bglll site of the ADH expression plasmid
pDB20LBglII (Berger et al., 1992).
Co-immunoprecipitations dada2 strains carrying a 2gi plasmid expressing
either ADA2HA (pADA2HA) or ADA2-6His (pADA2-6HisL) from the constitutive
ADH1 promoter were used to prepare nuclear extracts (Lue and Kornberg,
1987). Nuclear extracts were diluted to approximately 2mg/ml in IP buffer (10%
glycerol, 50mM Hepes KOH pH7.3, 100mM Kglutamate pH7.3, 0.5mM DTT,
6mM MgOAc, 1mM EGTA, 0.1% NP40 and protease inhibitors(Berger et al.,
1990)). 6jg of purified recombinant GAL4(1-147)-VP16((413-490) or (413-
456)) was then added to 1ml of extract and incubated for 3 hours at 40C. After
two centrifugations to clear the reactions, the extract was mixed with 25~l of a
slurry of protein A-agarose beads (Sigma) crosslinked to purified anti-HA
monoclonal antibody (Berkeley Antibody Co.) (Harlow and Lane, 1988). After
an overnight incubation at 40C the beads were pelleted by centrifugation and
washed six times with IP buffer. Then bound proteins were eluted from the
antibody by incubation with img/ml HA peptide (Berkeley Antibody Co.) (Field
et al., 1988). Eluants were precipitated with 10% trichloroacetic acid before
SDS polyacrylamide gel electrophoresis and transfer to Immobilon-P
membranes (Millipore). Western blots were probed with anti-HA or anti-VP16
antibody and visualized using the Lumi-Phos chemi-luminescent system
(Boeringher Mannheim).
Yeast Manipulations. The lexA reporter plasmid is YEp21-Sc3423 (Hope
and Struhl, 1986) or pRBHIS (Marcus et al., 1994) . Yeast manipulations and 3-
galactosidase assays were performed as in Pifa et. al (Pifia et al., 1993). All
strains were BWG1-7a and its derivatives or PSy316 (Berger et al., 1992; Piia
et al., 1993).
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Fig 1 GAL4-VP16 specifically co-immunoprecipitates with ADA2. In brief,
extracts containing either HA tagged or untagged ADA2 were mixed with
recombinant GAL4-VP16, and incubated with agarose beads covalently
coupled to the anti-HA monoclonal antibody. After the beads were collected
and washed, proteins bound to the antibody were eluted with HA peptide,
subjected to gel electrophoresis, and analyzed on the Western blots shown.
Panel a. shows a Western blot probed with anti-HA antibody (Berkeley Antibody
Co.). The lanes labeled '+' contain ADA2HA extract while the lanes labeled '-'
contain untagged ADA2 extract. Lanes labeled 'start' contain material prior to
the immunoprecipitation and the lanes marked 'super' contain supernatant that
did not bind to the beads. The material eluted with the HA peptide was loaded
in the lanes marked 'eluant'. The faint band in the eluant '-' lane that runs
slightly slower than ADA2 is a small amount of IgG heavy chain that has
-leached off the agarose beads. Panel b. shows a Western blot from the same
experiment that was probed with anti-VP16 antibody (generous gift of S. Berger,












Fig. 2 The full VP16 activation domain but not a version truncated
at residue 456 co-immunoprecipitates with ADA2. a. The results of a co-
immunoprecipitation experiment with ADA2 and the full VP16 activation domain
(residues 413 to 490) were analyzed by Western blot probed with anti-VP16
antibody. b. A Western blot from an experiment identical to that in part a except
ADA2 was co-immunoprecipitated with a version of VP16 truncated at residue
456 and then analyzed with anti-VP16 antibody. The high-molecular-weight
band in b represents GAL4-VP16 dimers that, presumably, have become cross-
















Fig 3. VP16 residues 413-470 comprise a potent, and ADA2-dependent,
activation domain. (Upper) A wild type strain (BWG1-7a) and an isogenic
Aada2 strain were transformed with the indicated lexA-VP16 fusion plasmid and
a lacZ reporter with one lexA binding site upstream of the CYC1 promoter
(Berger et al., 1992; Hope and Struhl, 1986). Fusions contain lexA residues 1
to 202 and the indicated residues of VP16. The entry labeled 413-470FA has
the substitution of an alanine for a phenylalanine at residue 442 (Cress and
Triezenberg, 1991). (Lower) Activity of a lexA fusion with the C-terminal portion
of VP16 is ADA2 independent. '-' indicates that no part of VP16 was fused to
the DNA binding domain. 13-galactosidase activity was determined and the
specific activity is indicated on the x-axis. Mean values are shown; 3-6
independent experiments were performed for each fusion construct and the
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Fig. 4 LexA-ADA2 is an ADA3 dependent transcriptional activator. The top
panel shows that ADA3 regulates the activity of the lexA-ADA2 fusion. The
lower panel shows that the activity of lexA-HAP4 is relatively insensitive to the
levels of ADA3. The x-axis indicates 3-galactosidase specific activity. The
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The ADAs - ADA 1, ADA2, ADA3, ADA5, and GCN5 - were identified
in a screen designed to isolate the target of transcriptional
activation domains. Further studies have shown that the ADAs
have the properties expected of genes encoding transcriptional
adaptors, which are factors proposed to mediate the interaction
between transcriptional activators and the general transcription
machinery. ADA2 is shown to directly bind to the VP16 activation
domain but not to a double Phe-->Ala substitution mutant. The
ADAs interact genetically with the SRBs and the CTD of RNA
polymerase II in a manner which suggests that the ADAs and the
SRBs function in parallel and that both mediate their effect by
interacting with the CTD. Furthermore, a complex containing all of
the known ADA proteins was partially purified from yeast extract,
and most of the ADA complex was found associated with RNA Pol II.
Moreover, we show that in vitro the ADA complex can bind to the
CTD specifically. Together these findings are consistent with a
model in which the ADAs function by associating with Pol II, and in




The expression of protein coding genes, which in eukaryotes are
transcribed by RNA polymerase II (Pol II), is often regulated by transcriptional
activation (Guarente, 1992). Most Pol II promoters have a TATA box located just
upstream of the transcription start site. This sequence element serves as the
binding site for the TATA-binding protein (TBP) which then nucleates the
assembly of the transcription initiation complex. However, different cis-acting
sites, termed UAS or enhancer elements, located hundreds (in yeast) or
thousands (in higher eukaryotes) of base pairs away from the TATA box, are
necessary for transcriptional activation. These elements serve as the binding
sites for transcriptional activators which contain a domain dedicated to binding
specific DNA sequences as well as a domain necessary for transcriptional
activation (Hope and Struhl, 1986). The mechanism by which these domains
activate transcription has been the focus of much research. Transcriptional
coactivators (or adaptors) are proposed to function by mediating the interaction
between activation domains and the general transcription machinery (Berger et
al., 1990; Kelleher III et al., 1990; Pugh and Tjian, 1990).
Factors of the coactivator/adaptor class have been identified by
biochemical purification and in genetic screens. The best studied coactivators,
the TBP associated factors or TAFs, facilitate the action of numerous activators
in vitro. In vivo studies have focused on genetic screens designed to identify
transcriptional coactivators. Coactivators identified in genetic selections include
the SRB genes (Hengartner et al., 1995 and references therein), the ADA genes
(Berger et al., 1992), and SUB1 (Knaus et al., 1996). Other screens, for
example the SPT (Winston, 1992), SWIISNF (Neigeborn and Carlson, 1984;
Stern et al., 1984), and CCR (Denis et al., 1994) screens, isolated mutants with
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broad pleiotropic transcription defects suggesting that the mutations may lie in
genes whose products are also involved in transcriptional activation.
The SRB genes were identified as suppressors of the conditional
phenotypes caused by truncation of the carboxy-terminal-domain (CTD) of RNA
polymerase II. The CTD is a conserved structure consisting of a repeated
heptapeptide sequence at the C-terminus of the largest subunit of polymerase
(RPB1). The CTD is essential for viability in yeast (Scafe et al., 1990), and it is
necessary for transcriptional activation in both yeast and mammalian cells
(Gerber et al., 1995; Scafe et al., 1990). In yeast, wild type RBP1 contains
twenty-six copies of the CTD heptapeptide repeat. Interestingly, truncation of
the CTD leaving only eleven repeats causes a number of conditional
phenotypes. These conditional phenotypes, which include temperature and
cold sensitivity as well as inositol auxotrophy, are suppressed by mutations in
the SRB genes (Scafe et al., 1990).
Interestingly, the SRB genes do not all have identical phenotypes. Some
SRB genes were identified as dominant suppressors of CTD truncations. This
suggests that they normally stimulate transcription through their interaction with
the CTD, and that these dominant alleles have increased stimulatory activity.
Two of these genes, SRB2 and SRB5, are not essential for viability, but loss-of-
function alleles of these genes exacerbate the phenotypes caused by CTD
truncations. In other words, SRB2 or SRB5 deletions in combination with CTD
truncations lead to phenotypes more severe than either an SRB deletion or
CTD truncation alone. In contrast, mutations in SRB 7, 8, 9, 10, and 11 were
isolated as recessive suppressors of CTD truncations suggesting that they
normally function to repress transcriptional activity through their interaction with
the CTD.
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Analysis of the SRB proteins during the fractionation of yeast whole cell
extracts has identified a novel form of RNA polymerase II called the
holoenzyme. This complex contains the twelve subunits of RNA polymerase II
as well as approximately twenty-five other polypeptides including the proteins
encoded by the nine SRB genes, the components of the SWI/SNF complex,
SIN4, RGR1, and GAL11 (Hengartner et al., 1995; Kim et al., 1994; Koleske and
Young, 1994; Li et al., 1995; Liao et al., 1995; Thompson et al., 1993; Wilson et
al., 1996). The holoenzyme also contains all of the general transcription factors
except TBP and TFIIE. The holoenzyme is capable of mediating activated
transcription in vitro with the addition of only TBP and TFIIE (Koleske and
Young, 1994). The TAFs are not required for this activity, which is in contrast to
findings from the fractionation of mammalian and Drosophila in vitro
transcription systems (Tjian and Maniatis, 1994). The isolation of the SRB
genes and the discovery of the holoenzyme highlights the power of coupling
yeast genetics and biochemistry to study transcription. Moreover, recent work
has also identified a large holoenzyme-like activity in mammalian extracts and a
human homolog of an SRB gene has been identified, further emphasizing that
the use of yeast genetics to study transcription often uncovers novel but
evolutionarily conserved aspects of the transcriptional mechanism (Chao et al.,
1996; Ossipow et al., 1995).
The ADA genes, ADA 1, ADA2, ADA3, ADA5 and GCN5, were identified
in a screen specifically designed to isolate the in vivo target of transcriptional
activation domains (Berger et al., 1992; Marcus et al., 1996; Marcus et al., 1994;
Piia et al., 1993; Horiuchi and Guarente, 1996). In this screen, the chimeric
activator GAL4-VP16, containing the GAL4 DNA binding domain fused to the
powerful acidic activation domain from the Herpes simplex virus VP16 gene,
was overexpressed causing severe toxicity in yeast cells. Since this toxicity
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correlates with the potency of transcriptional activation, it was postulated that
toxicity was due to the sequestration of the general transcription machinery by
GAL4-VP16 (Berger et al., 1992). We further predicted that if adaptors bridged
the interaction between activation domains and the general transcription
factors, mutations which relieve GAL4-VP16 mediated toxicity would identify
genes, termed ADA, which encode adaptor proteins.
Further experiments have shown that the ADAs have the properties
expected of an adaptor. ada2, ada3, and gcn5 mutants exhibit defects in VP16
and GCN4 mediated transcriptional activation. Furthermore, ADA2 or ADA3
themselves can activate transcription when tethered to the DNA at sites near the
promoter. Mutations in adal and ada5 cause defects in transcriptional
activation mediated by many transcriptional activators including GCN4.
Additionally ada 1 and ada5 mutants have two other phenotypes, inositol
auxotrophy and Spt-, which are commonly found in mutants with transcription
defects. In fact, ADA5 is identical to SPT20 (Horiuchi and Guarente, 1996;
Marcus et al., 1996; Roberts and Winston, 1996).
The adaptor model also predicts that the ADAs should interact with
activation domains. Consistent with this prediction, two acidic activation
domains which require the ADAs for activity in vivo and in vitro have been
shown to interact with the ADAs (Barlev et al., 1995; Berger et al., 1992;
Silverman et al., 1994). In fact, ADA5 directly binds to the VP16 activation
domain (Marcus et al., 1996); ADA2 directly binds to VP16 (Barlev et al., 1995)
and to an activation domain from ADR1; and GCN5 binds to a different
activation domain from ADR1 (C. Denis, personal communication).
The ADAs seem to function together as a complex. Double mutant
combinations of any two the ada genes possess phenotypes no more severe
than the worst single mutant. In addition, the transcriptional activity shown by
74
ADA2 and ADA3 when tethered to promoters is dependent on the levels of the
other ADAs. Furthermore, ADA2, ADA3, and GCN5 can form a complex in vitro.
Together these data argue that the ADA proteins function as a complex in order
to mediate transcriptional activation.
Recent studies have discovered one mechanism by which the ADA
complex might function as a coactivator. A GCN5 homolog from Tetrahymena
was purified because it is a histone specific acetyltransferase. Yeast GCN5 has
this same activity (Brownell et al., 1996). This may explain the observation that
acetylated histones are preferentially associated with actively transcribed
genes. Histone acetylation is believed to weaken the nucleosome-DNA
interaction and thus facilitate transcription. In addition to this Tetrahymena
GCN5, human homologs of both ADA2 and GCN5 have recently been isolated,
suggesting that the role of the ADAs in transcriptional activation is conserved
throughout all eukaryotes (Candau et al., 1996).
To further understand the role of the ADAs in transcription, especially
how they relate to other well characterized components of the transcriptional
machinery, we have continued the genetic and biochemical analysis of the ADA
genes. The evidence presented here demonstrates that the ADAs form a
complex that is capable of bridging the interaction between activation domains
and RNA polymerase II. These findings link Pol II directly to the ADA complex
which includes GCN5, a histone acetylating enzyme.
RESULTS
ADA2 does not bind to a double Phe-->Ala VP16 mutant
Previous studies using yeast extracts have shown that the ADA complex
binds to the acidic activation domains of VP16 and GCN4 but not to a truncated
version of VP16 or the HAP4 activation domain (Barlev et al., 1995; Silverman
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et al., 1994). Experiments with recombinant proteins have shown that the N-
terminal one-third of ADA2 can directly interact with the VP16 activation domain
(Barlev et al., 1995). In order to obtain more decisive evidence for the biological
relevance of this interaction, the ADA2-VP16 interaction was further analyzed
by testing the ability of ADA2 to bind a double Phe-->Ala VP16 mutant. Three
GST-VP16 variants were utilized in this experiment: the full length VP16
activation domain (amino acids 413-490) which depends on ADA2 for its
activity; VP16A456 (amino acids 413-456), which has very little activity in vivo
(1% of full length); and VP16FAFA, a mutant which contains two substitutions
(Phe442 to Ala and Phe475 to Ala) in the context of the full length activation
domain. The double point mutant is important because these two substitutions
create an activation domain that has very little activity in vivo but maintains its
size and charge (Regier et al., 1993). GST-VP16 fusion proteins were purified
from E. coli and incubated with in vitro translated ADA2. Glutathione-
Sepharose beads were used to precipitate GST fusions and associated
proteins. The beads were washed, and bound proteins were eluted with
glutathione, separated by electrophoresis and autoradiographed. In this assay
(see figure 1) the full length VP16 protein (lane marked WT) bound ADA2 while
the truncated protein (lane marked A) did not; moreover the double point mutant
(lane marked FF) did not interact with ADA2. This experiment strengthens the
claim that the binding of ADA2, and by inference the ADA complex, to activation
domains is functionally relevant.
ada mutations exacerbate the phenotypes of CTD truncations
In yeast, sequential truncations of the RPB1 CTD heptapeptide repeats
cause increasingly severe phenotypes (See Introduction). An RPB1 gene
containing only eleven heptapeptide repeats, instead of the wildtype twenty-six,
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causes conditional phenotypes (Scafe et al., 1990). However, when the same
truncation is combined with Asrb2 or Asrb5 mutations, the resulting strain is
inviable. This synthetic enhancement suggests that the SRB2 and SRB5
proteins, and presumably the proteins encoded by the other dominant SRB
genes, are necessary to enhance the functioning of Pol II through their
interaction with the CTD.
Since the ada mutants have similar phenotypes to srb2 and srb5 strains,
such as slow growth and temperature sensitivity, it was of interest to test
whether ada mutations also interact with CTD truncations. In order to test this
possibility, the strain JAy47, which carries an RPB1 gene controlled by the GAL
promoter, was employed (Archambault et al., 1992). This strain grows only
when galactose is used as the carbon source. In the presence of an alternate
source of RPB1, i.e. from a plasmid, this strain can grow on glucose
(Archambault et al., 1992). The genes for ADA 1, ADA2, and ADA3 were
deleted in JAy47. As shown in Figure 2, these strains (JAy47, JAy47Aadal,
JAy47Aada2 and JAy47Aada3) are inviable on glucose media when they do not
contain another copy of RPB1 (see sector marked vector), but grow when a
wildtype copy of RPB1 is expressed from a plasmid (see sector marked
wildtype). Also, the Ada+ strains (row marked wildtype) expressing RPB1
genes encoding thirteen, eleven, nine, and seven heptapeptide repeats exhibit
the expected growth phenotypes. A strain that express an RBP1 allele with
eleven heptapeptide repeats grows as well as a strain expressing wildtype
RPB1 at 220C, but is cold and temperature sensitive as expected (data not
shown). At 220C the strain expressing the nine repeat allele grows slowly as
expected in this genetic background (Rick Young personal communication),
and the strain with only seven repeats is inviable (See top left panel of Figure 2,
sectors marked, 13, 11, 9, and 7 repeats respectively.) (Scafe et al., 1990).
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As expected Aada2 or Aada3 strains with a full length CTD display no
obvious phenotypes on rich media while the Aada 1 strain has a mild growth
defect (Berger et al., 1992; Horiuchi and Guarente, 1996; Piia et al., 1993).
However, the growth of strains with CTD truncations is greatly slowed when
combined with the Aada alleles. When combined with an Aada mutation, strains
with the nine CTD repeats are inviable and strains with eleven or thirteen CTD
repeats grow very poorly (or not at all in the case of the Aadal strain). (See the
left column of Figure 2, rows labeled Aada 1, Aada2, or Aada3 compared to top
row labeled wildtype.)
Importantly, this synthetic enhancement is specific to CTD truncation
mutations. The right hand column of figure 2 shows the phenotypes of six other
rpb1 alleles which have mutations that do not lie in the CTD. All of these
mutants are temperature sensitive (data not shown and (Thompson et al.,
1993)). However, none of these mutants have a synthetic phenotype when
combined with ada deletions. In other words, the synthetic phenotype caused
by combining rpbl mutations and ada deletions is specific to those mutations in
polymerase which weaken the ability of the CTD to function. This genetic
interaction suggests that the ADAs function in a pathway with CTD in order to
activate transcription.
ada, srb2 double mutants exhibit synthetic lethality
The genetic data above suggest the possibility that the ADAs may
function in a manner similar to the dominant class of SRBs. Loss-of-function
mutations in either the ADA genes or the SRB2 and SRB5 genes exacerbate
the phenotypes caused by CTD truncations. In addition, srb2 and srb5 deletion
strains have growth phenotypes similar to ada deletions. These similarities
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suggest that the ADAs and the dominant class of SRB genes may function in
parallel activation pathways.
In order to determine if the ADAs function in parallel to SRB2, double
mutants were constructed. To clearly determine the viability of ada, srb2 double
mutants, a plasmid shuffle system was utilized. First, the deletion strains,
Aada2, Aada3, Agcn5, and the isogenic wildtype strain were transformed with a
URA3 marked plasmid carrying the appropriate ADA gene (or a similarly
marked vector in the wildtype strain) creating four Ada+ Ura+ strains.
Subsequently these strains were transformed with a HIS3 marked SRB2
disruption construct and Asrb2 strains were isolated. When the ADA plasmid
(marked pADA in the Figure 3 key) is maintained, these strains grow well at
room temperature (see upper plate of Figure 3). As expected, the Asrb2 strains
are temperature sensitive (data not shown). However, when strains lacking the
ADA gene are selected, using 5-Fluoroorotic acid (5-FOA) to select against the
URA3 marked ADA plasmid, the double mutants show a severe growth defect
(see lower plate, sectors marked Aada Asrb2). In contrast, strains containing
only the Asrb2 mutation or strains containing only an Aada mutation grow
perfectly well on 5-FOA. The synthetic phenotype caused by a combination of
ADA and SRB2 deletions is consistent with the hypothesis that the ADAs
function in a pathway that is parallel and partially redundant to the dominant
SRBs. The genetic interactions of these genes with CTD truncations suggest
that their gene products both function by interacting with the CTD of Pol II.
The ADAs interact with the carboxy-terminal domain of RNA
polymerase II
In order to determine if the ADAs physically interact with the CTD as
predicted by the genetic data, we analyzed eluants from a CTD column and
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found ADA2 and ADA3 in the 1M Urea elution (data not shown, N.S. Dave
Chao, Richard Young and L.G.), suggesting the ADAs interact with the CTD
(Thompson et al., 1993). To study this further, a GST-CTD precipitation assay
was utilized (Wilson et al., 1996). A GST-CTD fusion, or as a control GST
alone, was crosslinked to Sepharose beads. These beads were incubated with
partially purified ADA complex (see below for details), and bound proteins were
washed extensively, eluted in high salt and analyzed by immunoblot. As shown
in Figure 4a, ADA1, ADA2, and ADA3 bound to the GST-CTD beads but not to
the GST beads. As displayed, approximately 10% of the onput ADA proteins
bound to CTD beads in this assay (compare lanes 2 and 5 of Fig. 4a) which is
consistent with other experiments using immobilized CTD proteins (R. Young
personal communication). As shown in Figure 4b, a silver stained
polyacrylamide gel from the same experiment, the binding of the ADAs to the
CTD was specific. Clearly the GST-CTD beads bound far less than 10% of all
the proteins in the starting material (compare lane 9 to 6). This specific
interaction suggests that the CTD is the binding target of the ADAs.
The ADA proteins cofractionate with core RNA polymerase II
To obtain more definitive evidence that the ADA complex binds to RNA
Pol II, yeast extract was fractionated on three successive columns. Whole cell
extract was prepared from a strain carrying pPADA26HIS, which expresses a 6-
histidine tagged ADA2 gene from its own promoter. The tagged version of
ADA2 fully complements a deletion of the gene. The extract was first
fractionated on a Bio-Rex 70 column and step eluted with increasing
concentrations of potassium acetate. Interestingly, the ADAs - ADA1, ADA2,
ADA3, GCN5 and ADA5 - cofractionate in two different elutions, the 600mM step
which contains about 60% of the ADAs, and the 1200mM elution which contains
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about 40% of the ADAs (data not shown). The two ADA enriched fractions were
then separately fractionated over a Nickel-NTA agarose column. Following the
Nickel column the ADA enriched fractions were fractionated further on a Poros
HQ-20 anion exchange column and eluted with a potassium acetate gradient.
Figure 5a shows an immunoblot across a portion of this final gradient. The
ADAs cofractionate, peaking in fractions containing approximately 1100mM salt.
This cofractionation is true for both the material originally from the Bio-Rex
600mM elution (BR600) and the material from the Bio-Rex 1200mM elution
(BR1200) (See Figure 5a and 5c). The peak of ADA protein from the HQ-20
column represents at least a 500-fold purification. The cofractionation strongly
supports earlier findings that ADA2, ADA3, ADA5 and GCN5 interact in vitro and
in vivo (Candau and Berger, 1996; Horiuchi et al., 1995; Marcus et al., 1996;
Marcus et al., 1994; Silverman et al., 1994). In total, this partial purification
greatly strengthens the notion that the ADAs (ADA1, ADA2, ADA3, ADA5, and
GCN5) function together in a complex to facilitate transcriptional activation.
The partially purified ADA complex was further analyzed for other
cofractionating transcription factors. Interestingly, RNA polymerase II, as
assayed with anti-RPB1 monoclonal antibodies, cofractionates precisely with
the ADAs during the final elution gradient. This is true only for the material
originally eluted from the Bio-Rex 70 in 600mM salt (BR600); no RPB1 is
detected in the BR1200 material (See figure 5a compared to 5c). It is possible
that this complex represents the holoenzyme, as ADA2 is present in the
holoenzyme at levels less than one-tenth that of the SRB proteins (data not
shown). Therefore, the ADA enriched fractions were analyzed for the presence
of holoenzyme components. Interestingly, neither SRB4, SRB5, nor SW13
cofractionate with the ADAs and polymerase (see figure 5b). In the BR600
material the SRB/SWI complex elutes from the HQ-20 column at a much lower
salt concentration than the ADA/Pol II complex. The BR1200 material does not
contain any of these holoenzyme components (data not shown). This result
suggests either that the SRB/SWI proteins detected here represent free SRB
complex, or that the SRB complex can be stripped from polymerase under
conditions where the ADAs are still tightly associated. Similar to the SRB/SWI
proteins, TFIIH binds to the HQ-20 column but elutes in lower salt than the
ADA/Pol II complex. TBP, TFIIB, and TFIIE do not cofractionate with the ADAs;
they flowthrough the final HQ-20 column. None of these general transcription
factors are found in the BR1200 material (data not shown). These findings
suggest that in vivo the ADAs exist in two pools: one of free ADA complex
represented by the BR1200 material; and another where the ADAs are tightly
associated with RNA polymerase II. This polymerase association represents a
novel complex that is different from the previously characterized holoenzyme as
it does not cofractionate with known components of the holoenzyme. Moreover,
this association with polymerase validates both the in vivo and in vitro
interactions between the ADAs and the CTD of RNA Pol II.
DISCUSSION
ADA2 interacts only with functional activation domains
This study further examines the genetic and biochemical properties of the
ADAs. The importance of the ADA2-VP16 interaction is highlighted by two
findings. The VP16 activation domain requires ADA2 for its full activation
potential in vivo and in vitro (Barley et al., 1995; Berger et al., 1992; Silverman
et al., 1994). Secondly, this interaction occurs only with variants of VP16 that
mediate the activation of transcription. As shown earlier, and demonstrated
here, ADA2 does not bind to a truncated form of VP16, VP16A456, that has very
little activity in vivo. Furthermore, the experiments presented here demonstrate
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that ADA2 does not bind a VP16 mutant with a double phenylalanine to alanine
substitution. This mutation has very little activity in vivo but retains the same
charge and size characteristics of the wildtype protein. This significantly
strengthens the argument that the ADA2-VP16 interaction is biologically
relevant.
Interestingly, the ADA2-activation domain interaction is not the only
connection between the ADA complex and activation domains. Like ADA2,
ADA5 has been shown to directly interact with the full length VP16 activation
domain but not with VP16A456 or VP16FAFA (Marcus et al., 1996); and GCN5
has also been shown to bind an activation domain from the ADR1 protein (C.
Denis, personal communication). Thus, it appears that the ADA complex has
multiple interactions with activation domains. In addition, different activation
domains may interact with different subunits of the ADA complex. These
interactions may recruit the ADAs to promoters during transcriptional activation.
The VP16 interaction was previously shown to be mediated by the N-
terminal one-third of ADA2 (Barlev et al., 1995). Interestingly, this region is
highly conserved between the yeast ADA2 and the recently isolated human
(Candau et al., 1996), S. pombe, and K. lactis ADA2 homologs (unpublished
data, Thomas Oehler, Paul Spellman, N.S. and L.G.). This suggests that the
ADA2-VP16 interaction also occurs in mammalian cells. The role of the human
ADA2 awaits further study; however, the conservation of many factors involved
in transcription suggests that the human ADAs will function in a manner similar
to the yeast ADAs.
The ADAs and SRB2-SRB5 act in parallel to stimulate CTD function
Genetic interactions have often led to significant insights into the in vivo
role of transcription factors. For example, the suppression of swi and snf
83
mutants by alterations in chromatin first suggested that the SWI/SNF proteins
might counteract chromatin mediated repression, an idea which has
subsequently been verified by biochemical studies (Cairns et al., 1994; C8tM et
al., 1994; Imbalzano et al., 1994; Kwon et al., 1994; Peterson et al., 1994;
Peterson and Herskowitz, 1992; Winston and Carlson, 1992). Synthetic
lethality between non-null mutations in an essential gene and mutations in
other genes provides genetic evidence that the two gene products function in
the same pathway (Guarente, 1994). Since the CTD is essential for viability, the
synthetic lethality between ada mutations and non-lethal CTD truncations
suggests that the ADAs and the CTD function in a common pathway. The
synthetic lethality between the ADAs and the CTD is allele specific; other
mutations in RPB1 which lie outside the CTD are not synthetically lethal with
ada deletions. This allele specificity argues for a specific link between the CTD
and the ADAs.
The hypothesis that the ADAs are necessary for the full functioning of the
CTD suggests that they may act in parallel to the dominant SRBs (SRB2, 4, 5
and 6). The SRB proteins are known to physically associate with RNA Pol II as
components of the RNA polymerase II holoenzyme. Furthermore, at the genetic
level srb2 and srb5 loss-of-function mutations interact with the CTD in a
manner similar to ada deletions. srb2 and srb5 deletions exacerbate the effects
of CTD truncations, suggesting that SRB2 and SRB5 proteins function by
stimulating transcription through their interaction with the CTD (Thompson et al.,
1993). Consistent with the model that the ADAs and these SRBs function in
parallel, we found that ada deletions have a synthetic phenotype when
combined with srb2 deletions. Synthetic lethality between null alleles of two
non-essential genes indicates that these genes function in parallel (Guarente,
1994). This supports the hypothesis that the ADAs and SRB2 function in
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parallel activation pathways. A simple model incorporating all the genetic data
argues that both the ADA proteins and the SRB2 and SRB5 proteins enhance
the ability of the CTD to function during the activation of transcription. Deleting
one gene of either class does not cause inviability because the other class of
genes can provide the same or similar activity. However, eliminating the
function of both groups of genes causes a severe slow growth phenotype
because the CTD can no longer function properly.
The ADA complex can associate with RNA polymerase II.
The data presented here strengthens the model that the ADAs function
as a complex in order to activate transcription (Horiuchi et al., 1995; Silverman
et al., 1994). Earlier studies demonstrated that ADA2, ADA3, and GCN5 can
form a trimeric complex in vitro (Horiuchi et al., 1995; Marcus et al., 1994).
Previous work also suggested that the ADA complex functions in vivo to activate
transcription (Silverman et al., 1994). In this study an ADA complex containing
ADA1, ADA2, ADA3, ADA5 and GCN5 was purified from yeast whole cell
extract, supporting earlier suggestions of an ADA complex.
Moreover, the ADA complex specifically cofractionates with RNA
polymerase II1. The specificity of this cofractionation is demonstrated by the fact
that none of the other general transcription factors tested, neither TBP, TFIIB,
TFIIE, nor TFIIH cofractionate with the ADAs. In addition, the ADA complex can
bind the CTD specifically, which validates the genetic interactions observed
between the ADAs and the CTD. Furthermore, neither SRB4, SRB5, nor SWI3
fractionate with the ADAs and Pol II arguing that the ADA-Pol II complex is
different from the holoenzyme and is consistent with the idea that it functions in
parallel to the SRBs.
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Taken together, the data presented here support a model whereby some
activators interact with the ADA-Pol II complex in order to mediate the activation
of transcription. The ADA-activation domain interaction may serve to recruit
RNA polymerase II to promoters through the association of the ADA complex
with Pol II. But it is also possible that the ADA-CTD connection affects some
other step in transcription initiation that is enhanced by activators. For example,
it may stabilize a larger complex which also contains TBP, as suggested by two
previous studies (Barlev et al., 1995; Marcus et al., 1996). Also, the association
of the ADAs with polymerase may allow for both the recruitment of polymerase
and the concomitant acetylation of histones, since GCN5 has recently been
shown to have histone specific acetyltransferase activity (Brownell et al., 1996).
Acetylated histones are found preferentially at actively transcribed genes
(Hebbes et al., 1988). The fact that not all of the ADA complex is found
complexed with polymerase, i.e. the BR1200 fraction, suggests that there is a
pool of free ADA complex available in the cell. The importance of such a free
pool is not clear. One possibility is that the association of the ADA complex with
polymerase could be regulated in order to modulate the overall level of
transcriptional activation.
Future experiments will focus on two important aspects of ADA molecular
biology. There is no reason to believe that all the members of the ADA complex
have been identified. If the ADA complex is as complicated as the SRB
complex, it is not necessarily true that mutations in all the members of the
complex will have similar phenotypes. In fact, mutations in the known
components of the ADA complex do not all have identical phenotypes; ada2,
ada3, and gcn5 strains have very similar properties, but ada 1 and ada5 mutants
have additional phenotypes such as Spt- and inositol auxotrophy (Horiuchi and
Guarente, 1996; Marcus et al., 1996; Roberts and Winston, 1996). Therefore,
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continued purification of the complex is of utmost interest to identify all of its
components. One protein that is predicted to be in the ADA complex is SPT7,
because spt7 strains have phenotypes very similar to ada5 mutants (Roberts
and Winston, 1996). Most importantly, future experiments will also focus on the
characterization of the biochemical activities found in the ADA complex.
Material and Methods
Yeast strains and plasmids
All strains used have been described previously (Berger et al., 1992;
Marcus et al., 1994; Pifia et al., 1993). CTD truncations were analyzed in the
strain JAy47 (Archambault et al., 1992). ADA deletions were constructed in this
strain using previously described deletion constructs pADA2KO for deletion of
ADA2 (Berger et al., 1992); pADA3KO for deletion of ADA3 (Marcus et al.,
1994); and pADA1KO for deletion of ADA 1 (Horiuchi and Guarente, 1996).
Candidate deletion strains were scored for slow growth on minimal galactose
media and mated to their cognate Ada- strain to score for proper integration of
the deletion plasmid. Finally, deletions were verified by transforming with the
proper ADA gene and scoring for complementation.
SRB2 deletions were constructed by transforming PSY316 and isogenic
ADA deletion strains with a 3.3kb fragment from pTK33 which replaces the
SRB2 gene with HIS3. Proper SRB2 deletions were selected based on their
growth phenotypes, non-complementation when mated to a Asrb2 strain, and
complementation by an SRB2 plasmid. As described in the text, the Aada
strains were transformed with the appropriate URA3 marked ADA plasmid prior
to disruption of SRB2. The Aada2 strain contained pNS3.8 (Berger et al.,
1992); the Aada3 strain contained pA3P2U (gift of S. Treadway); and the Agcn5
strain contained p5-1,2D (Marcus et al., 1994)
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To make the plasmid pPADA26HIS, pDB200CADA26HIS was digested
with Spel, filled-in with T4 DNA polymerase, and then digested with AffIl. The
fragment containing the C-terminal one-third of ADA2 fused to six histidines
followed by the ADH terminator was purified and cloned into pNS3.8 (Berger et
al., 1992) that had been digested with Afllt and Mscl. pDB200CADA26HIS is an
ARS/cen derivative of pADA26HIS (Silverman et al., 1994). This created a
plasmid which contains the ADA2 promoter expressing the ADA2-six histidine
fusion gene followed by the ADH terminator.
pGVPFAFA, the GST-VP16 expression vector, was made by amplifying
the VP16FAFA sequence from the plasmid pMSVP16FA442FA475 (a gift of S.
Triezenberg) and ligating into pGVP (Lin and Green, 1991).
The plasmids used for the CTD truncation experiments were pN11
(seven CTD repeats), pN15 (nine repeats), pC6 (eleven repeats), pV17
(thirteen repeats), and pRP114 (wildtype RPB1), all gifts from the Young lab.
GST pull down assays
GST-VP16 pull down experiments were performed as described
previously (Marcus et al., 1996) except Triton X-100 was not used in the buffer.
The ADA2 in vitro transcription/translation vector was also described previously
(Horiuchi et al., 1995). Briefly, 10Qg of purified GST fusion proteins were bound
to glutathione-Sepharose (Pharmacia), then 10pl of in vitro translated ADA2
and 20011 of S(300) buffer (20mM Hepes 7.6, 300mM potassium acetate, 25mM
magnesium acetate, 20% glycerol and protease inhibitors (Hengartner et al.,
1995)) were added. The beads were preblocked in 1 mg/ml E. coli extract and
the initial incubation was also done in the presence of this blocking extract.
After incubation for one hour, the beads were centrifuged, washed six times in
lml of S(300) buffer, and then bound proteins were eluted in S(300) buffer
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supplemented with 20mM reduced glutathione (Sigma). Eluted proteins were
separated by SDS-PAGE and autoradiographed. Following autoradiography,
the polyacrylamide gels were rehydrated and stained with Coomassie blue to
determine that equal amounts of the GST fusion proteins were bound to and
eluted from the beads (data not shown).
GST-CTD pull down experiments utilized either GST or GST-CTD protein
beads that were made by crosslinking the proteins to CNBr activated
Sepharose per the manufacturers protocol (Pharmacia). The proteins (a gift of
D. Chao and R. Young) were crosslinked at equal density, 5 milligrams protein
per milliliter of beads, and the crosslinking was equally efficient as determined
by Coomassie staining. Equal volumes of GST of GST-CTD beads (101) were
incubated with 1001l of partially purified ADA complex in a volume of 1ml of
S(300)1%T buffer (same as above except Triton X-100 was added to 1% and
no blocking agents were necessary). After binding for one hour on ice, beads
were pelleted, washed at least six times in 1ml S(300)1%T buffer, and bound
proteins were eluted with 1 M potassium chloride. Eluted proteins were
precipitated with trichloroacetic acid, separated by SDS-PAGE and analyzed by
Western blot.
Fractionation of whole cell extracts
Strain 1-7aAada2 (Berger et al., 1992) carrying pPADA26HIS was grown
in minimal media to yield approximately 500g wet weight of cells. Preparation
and fractionation of whole cell extract on a Bio-Rex 70 column (5xl0cm) was
performed as described by others (Sayre et al., 1992) except elutions were
performed with 250, 600 and 1200 mM potassium acetate. Elutions were
analyzed for the presence of ADA2 and ADA3 proteins by Western blot. The
relevant fractions from the 600mM potassium acetate and 1200mM potassium
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acetate elutions were pooled and dialyzed against Buffer N (20mM Hepes
KOH7.6, 10% glycerol, 300mM potassium acetate, 10mM B-mercaptoethanol,
and protease inhibitors). This material was then bound to an NTA-Ni agarose
column (1.5x10cm) and eluted with an imidazole gradient. Fractions enriched
in ADA2 and ADA3 were pooled and diluted into Buffer H (20mM Hepes
KOH7.6, 10% glycerol, 1mM DTT, ImM EDTA, and protease inhibitors) to a final
salt concentration of 100mM potassium acetate. This material was then
fractionated over a Poros HQ-20 column (4.6x100mm) (PerSeptive Biosystems)
with a elution gradient from 100mM to 1500mM potassium acetate of 10 column
volumes using the BioCAD Sprint apparatus (PerSeptive Biosystems).
Fractions from this column are used in the analysis shown in Figures 2 and 5.
Western blots and anti-sera
ADA1, ADA2, ADA3, ADA5 and GCN5 anti-sera were described elsewhere
(Horiuchi and Guarente, 1996; Marcus, 1995; Marcus et al., 1996; Marcus et al.,
1994). 8WG16 the anti-CTD monoclonal (Thompson et al., 1989), anti-TFB1,
anti-SRB5 (Koleske and Young, 1994), anti-SRB4 (Hengartner et al., 1995) and
anti-SWI3 (Peterson et al., 1994) antibodies were all described elsewhere.
Western blots were performed by standard techniques. ADA1, ADA2, and
ADA3 anti-sera were affinity purified using strip purification (Harlow and Lane,
1988), anti-ADA5 IgG molecules were purified on a Protein-A column. After
blocking and incubation with primary antibody, blots were washed and
incubated with secondary anti-rabbit (or anti-mouse for 8WG16) antibody
crosslinked to Horseradish peroxidase (Amersham) and visualized using the
ECL system (Amersham).
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Figure 1: ADA2 interacts with the wildtype VP16 activation domain but not with
the VP16FAFA mutant. GST-VP16 fusions were used to precipitate in vitro
translated 35S-labeled ADA2 (see Materials and Methods for details). The lane
marked OP contains 2% of the ADA2 protein that was loaded onto the beads.
The other lanes show the ADA2 protein that was precipitated with wildtype
VP16 (lane marked WT), or with VP16FAFA (lane marked FF), or with
VP16A456 (lane marked A). Wildtype GST-VP16 contains the full VP16
activation domain, residues 413-490. VP16FAFA is a double Phe to Ala
substitution mutant at residues 442 and 475 within the full length VP16
activation domain. VP16A456 is a truncation mutant of VP16 that contains
residues 413-456 of VP16. VP16FAFA and VP16A456 have very little activity in
vivo (Regier et al., 1993; Silverman et al., 1994). As demonstrated here, they






Figure 2: CTD truncations and ADA deletions show synthetic enhancement.
The top row is a key detailing which RBP1 allele each sector contains. Vector
indicates that the strain does not contain an RBP1 expressing plasmid. WT
indicates that a wildtype allele of RBP1 is expressed; 13 repeats, 11 repeats, 9
repeats, or 7 repeats indicates that RBP1 alleles with 13, 11, 9, or 7
heptapeptide repeats, respectively, are expressed. In the right hand column,
other rbpl alleles are expressed as indicated. The far left column indicates the
ADA genotype of the strains in each row. As is clearly exhibited, deletion of the
ADA genes makes the phenotypes caused by CTD truncations much more
severe. For example, compare the growth of strains expressing RBP1 alleles
with 9 repeats. Also, the effects were specific to CTD truncation mutations.
Compare the synthetic effects in the left column to the normal growth seen in the
column on the right. All strains were grown on glucose so that the endogenous




















Figure 3: SRB2, ADA double deletion mutations display synthetic phenotypes.
The top panel is a key for the lower two panels. Four strains, wildtype, Aada2,
Aada3, and Agcn5, were transformed with URA3 marked plasmids encoding,
respectively, either no ADA gene (pRS316), ADA2 (pADA2), ADA3(pADA3), or
GCN5 (pGCN5). This created four Ura+ Ada+ strains. Then the SRB2 gene
was replaced with the HIS3 gene. The middle panel shows growth of all strains
on rich media selecting for the URA3 marked ADA plasmids. The lower panel, a
plate containing 5-FOA, shows the phenotype of double ada, srb2 mutants
created after the loss of the ADA plasmid. As is clear in the lower panel,
deletion of ADA2, ADA3, or GCN5 in combination with the SRB2 deletion
causes a severe slow growth phenotype. However, in strains with only one
gene deleted, either the control wildtype strain that is always Ada+ or the strains
with an intact SRB2 gene, growth on 5-FOA occurs normally. Note, the double
mutants will form colonies after more than six days on 5-FOA plates, whereas
the control strains grow in less than two days. When these double mutant








Figure 4: The ADA complex binds to the CTD of RNA Pol II. Either GST or GST-
CTD beads were used to precipitate proteins from ADA enriched fractions (see
Material and Methods). (A) An immunoblot from this experiment that was
probed with antibodies to ADA1, ADA2 or ADA3 (as labeled). Lanes 1 and 2
were loaded with 40% and 10%, respectively, of the material which was added
to the protein-beads. Lanes 4 and 5 show the material that was eluted from the
GST or GST-CTD beads, respectively. By comparing lane 2 to lane 5 it is clear
that -10% of the ADA proteins which were loaded on the GST-CTD beads were
bound and eluted. However, no ADA proteins bound the control GST beads.
(B) Moreover, a silver stained polyacrylamide gel from the same experiment
shows that 10% of the total protein in the sample did not bind the GST-CTD
beads (compare lane 6 to lane 9). Note, that ADA2 protein is difficult to detect
because the antibody is not very sensitive (data not shown), but on close


















Figure 5: ADA1, ADA2, ADA3, ADA5, GCN5 and RNA Polymerase II
cofractionate. All panels display immunoblots probed with the indicated
antisera. Panels A and B show immunoblots of fractions from the HQ-20
column that was loaded with material originally from the Bio-Rex 70 600mM
potassium acetate elution (BR600). The onput, flowthrough, and every other
fraction, between fraction 14 and fraction 24, were probed as indicated at the
top of panel A. (A) ADA1, ADA2, ADA3, ADA5, GCN5, and RBP1 cofractionate
in a single peak near fraction 18. (B) These blots contain the same samples
and were loaded in the same order as panel A; they show that SRB4, SRB5,
SW13, and TFIIH (the p62 subunit encoded by TFB1) elute much earlier than the
ADA-Pol II complex. Other general transcription factors, TBP, TFIIB, and TFIIE
(the small subunit encoded by TFA2) do no bind this column and are found in
the flowthrough. (C) The material originating from the Bio-Rex 70 1200mM
KOAc elution (BR1200) was fractionated on a HQ-20 column as in panels A
and B and analyzed by immunoblot. ADA1, ADA2, ADA3, ADA5, and GCN5
cofractionate but no RBP1 is detected. (A control lane indicates that the a-RBP1
antibody would have detected RBP1 protein present in these fractions (data not
shown).) No other general transcriptional factors were found in the BR1200
material (data not shown).
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